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ABSTRACT
This thesis was undertaken to determine if there is any inter­
relationship between the two terminal enzymes of the haem bio­
synthetic pathway, protoporphyrinogen oxidase (PPO) and ferrochelatase, 
with particular reference to porphyria variegata (PV) and erythro­
poietic protoporphyria (EPP)• It has previously been found that both 
enzymes were deficient in PV and EPP, there being a qualitative 
difference in so far as ferrochelatase deficiency is concerned. 
Protoporphyrinogen oxidase (PPO) activity was measured in both EPP 
and PV patients and in the offspring of PV patients. In the same 
subjects, protoporphyrin formation by mitogen stimulated lymphocytes 
with 6-amino-laevulinic acid as substrate and in the presence of an 
iron chelator or iron, provided an indirect measurement for ferro­
chelatase. The results provided strong evidence that PPO and 
ferrochelatase were both defective in both diseases. Furthermore, 
the studies in the offspring of PV subjects showed normal ferrochelatase 
activity which would suggest that ferrochelatase deficiency is only 
manifested after puberty. Detailed studies in PV families suggested 
that reduced PPO activity may be a marker for carriers who evolve 
into PV patients in adulthood. Ferrochelatase was purified according 
to a method previously described. PPO was purified by anion exchange 
chromatography using a Pharmacia FPLC apparatus. A chromophore was 
found to be associated with PPO and preliminary studies suggested 
that it was FAD. Antibodies raised against ferrochelatase and PPO 
showed marked cross reactivity against the other enzyme and peptide 
maps for each enzyme showed marked structural similarities between 
them. In addition to clinical evidence interrelating PPO and 
ferrochelatase, these studies provided evidence for structural
homology between them.
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INTRODUCTION
In any study of the human porphyrias it is essential 
to begin with a review of the haem biosynthetic 
pathway (Fig 1). The enzyme ALA-synthetase 
(ALA-synthase) combines glycine and succinyl CoA to 
form the first precursor, delta-aminolaevulinic acid 
(ALA). Porphobilinogen (PBG) is formed from two 
molecules of ALA by the enzyme ALA dehydrase. Two 
enzymes, uroporphyrinogen-I-synthetase 
(porphobilinogen deaminase) and uroporphyrinogen 
cosynthase are required for condensation of four 
molecules of porphobilinogen for the formation of 
uroporphyrinogen. Uroporphyrinogen-cosynthase ensures 
that uroporphyrinogen type III isomer and not type I 
is produced. It is from the type III isomer that 
protoporphyrin IX is formed into which iron is 
inserted for the formation of haem. Uroporphyrinogen 
is an 8-carboxymolecule which is progressively 
decarboxilated by the enzyme urodecarboxylase to 
coproporphyrinogen, a 4-carboxy group. 
Coproporphyrinogen is further decarboxylated by 
coproporphyrinogen oxidase to form protoporphyrinogen; 
the latter is oxidised by protoporphyrinogen oxidase 
to protoporphyrin. Finally iron is inserted into 
protoporphyrin by ferrochelatase to form haem (1). 
ALA-synthetase is a mitochondrial enzyme but is not 
membrane bound (1). On the other hand the terminal 
three enzymes coproporphyrinogen oxidase,
2FIG.1; The haem biosynthetic pathway . Subcellular 
distribution of enzymes and intermediates in 
the synthesis of haem is shown 
' A.-CH2COOH; M.-CH3 ; P.-CH2CH2COOH. V.-CH-CH2
(1)
protoporphyrinogen oxidase and ferrochelatase are 
associated with or bound to the inner mitochondrial 
membrane (2,3). The rest of the enzymes in the haem 
biosynthetic pathway are in the cytosol (1). 
Biosynthesis of haem in the liver is controlled 
largely by the rate of production of ALA-synthetase 
(4). While the activity of ALA-synthetase is low and 
rate-limiting in the liver, activity of the other 
enzymes are in excess.
About 65 percent of haem produced in the liver is
utilized for the formation of microsomal P450, about
15 percent for the synthesis of catalase in the
peroxisomes, 6 percent for the formation of
mitochondrial cytochromes and 8 percent for the
formation of cytochrome b5 (5). A negative feedback
control by haem at the level of ALA-synthetase exists
in the liver. ALA-synthetase activity is stimulated
in the presence of xenobiotics and natural steroids
(7-10) and ALA synthetase activity is suppressed by
7hemm (6, 11-14) at concentrations as low as 10- M.
Porphyrins produced in the haem biosynthetic pathway 
are cyclic tetrapyrroles that display a distinctive 
absorption spectrum (15). The absorption spectrum 
consists of a major absorption band in the 400 nm 
region, called the Soret band, and four smaller 
absorption bands at longer wavelengths between 500 and 
630 nm (16). Metal free porphyrins omit an intense
4 .
red fluorescence upon excitation by long wavelength 
ultraviolet light ( 400 nm). Porphyrins chelated
with metals that have no unpaired electrons (e.g. Mg, 
Zn, Sn) also display strong fluorescence upon 
illumination with long wavelength U.V. light, whereas 
porphyrins chelated with paramagnetic metals do not 
fluoresce (17). For example, the magnesium porphyrin 
chelate chlorophyll fluoresce, whereas iron 
protoporphyrin IX (i.e. haem) does not. Upon 
illumination at U.V. wavelengths and in the presence 
of molecular oxygen, fluorescence of porphyrins causes 
photodynamic effects on cells and subcellular 
structures (17). Injury to cells in the presence of 
porphyrins appear to be the result of photodynamic 
damage to plasma and lysosomal membrane (17,18). The 
porphyrin precursors ALA and PBG do not fluoresce.
PBG when allowed to stand in sunlight is spontaneously 
converted to porphobilinogen which has a red colour. 
This is a valuable aid in the diagnosis of an acute 
attack in the hepatic porphyrias. The water solubility 
of porphyrins becomes greater as the number of 
carboxylic acid side chains increases. Uroporphyrin is 
most water soluble followed by coproporphyrin whereas 
protoporphyrin is so hydrophobic that it is excreted 
only in the bile. Uroporphyrin is excreted in urine 
and coproporphyrin into urine and stool. (17)
The human porphyrias are inherited and acquired 
disorders characterised by defects in specific enzymes
5.
of the haem biosynthetic pathway (Fig. 2). These 
defects cause the accumulation and excretion of 
chemical intermediates in haem synthesis and are 
responsible for a variety of clinical symptoms among 
which neurological abnormalities and cutaneous 
photosensitivity dominate. In 1954 Schmid et al., 
(19,20) divided the porphyrias into two types, 
erythropoietic and hepatic, depending on whether the 
overproduction of porphyrins or porphyrin precursors 
takes place primarily in the erythron or the liver.
In the erythropoietic porphhyrias there are increased 
levels of porphyrins in bone marrow and circulating 
erythrocytes, whereas porphyrins and porphyrin 
precursors are overproduced primarily in the liver in 
the hepatic porphyrias. Although enzyme defects are 
found in many tissues of porphyric patients these 
defects are not equally expressed in all tissues 
(1). Most human porphyrias are autosomal dominant 
inherited disorders, but congenital erythropoietic 
porphyria, erythrohepatic porphyria and ALA-dehydrase 
deficiency are autosomal recessive in their form of 
inheritance.
Erythropoietic porphyrias
Congenital Erythropoietic Porphyria
In congenital erythropoietic porphyria (CEP) there is
6.
ENZYMIC CHANGES IN THE PORPHYRIAS
ERYTHROPOIETIC HEPATIC
SUCCINYL -  CoA
+
GLYCINE
pyridoxal -  PO4 ALA-SYNTHETASE]
AIP
HC
PV
ALAD
ALA
ALA-DEHYDRASE VV 1ALAD
PBG
,____ _ URO III
IC E P jy y  COSYNTHETASE
URO I
SYNTHETASE y [aipj
URO'GEN I URO'GEN III
URO 
DEC/
COPRO'GEN III
ARBOXYLASE f  LE£l] Y Y  fEHPl
PROTO'GEN OXIDASE
COPRO'GEN OXIDASE Y [H C ]  
PROTO'GEN IX
PROTO
EPP | y y  FERROCHELATASE 
T T FE ++
HEME
Negative feedback
y  ENZYME ACTIVITY ± 50% OF NORMAL 
y y  ENZYME ACTIVITY 7-15% OR "MUCH LOWER" THAN NORMAL (CEP)
FIG. 2: Enzymic changes in the porphyrias
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by Dr. S. Kramer).
7.
a deficiency of uroporphyrinogen III cosynthetase 
activity (21), since in vitro studies of cells from 
patients, showed impaired formation of the type III 
porphyrin isomers relative to the type I isomer.
This disease is characterised by increased porphyrins 
in bone marrow, red cells, urine and faeces (1). CEP 
is a severe disorder with marked skin sensitivity 
beginning soon after birth and a considerable 
shortened life expectancy.
Erythropoietic protoporphyria
Erythropoietic protoporphyria was first clearly 
described by Magnus et al. 1961 (22) . In South Africa 
it is the third commonest type of porphyria and it was 
first described by Sweeney et al., 1963 (23). Leeming 
and Kramer, 1968 (24) then reported another series of 
cases in South Africa. The disease is suspected to 
be inherited as an autosomal dominant trait (25).
The main clinical features are the dermatological 
manifestations which are somewhat different from those 
described in other types of porphyria. The skin when 
exposed to sun itches and becomes erythematous and 
swollen. The subsequent changes are those of 
verruginous thickening of the skin of the dorsum of 
the hands and nose. The skin lesions are present 
from as early as three years of age. In this disease 
there are high levels of protoporphyrin in the red 
cells and increased excretion of protoporphyrin in the
8.
stool in some cases. The dermatological 
manifestations are not the only features of the 
disease.
Hepatic changes with portal fibrosis and intrahepatic 
deposits of pigment have been described in a number of 
cases who died in hepatic failure.
Assays of ferrochelatase activity in bone marrow 
reticulocytes (27,28),1iver, cultured fibroblast (29) 
and buffy coat lysates (28,30,31) showed that this 
enzyme is deficient in EPP. In this disease 
protoporphyrin starts to accumulate in bone marrow 
normoblasts just before the nucleus is extruded and 
continues through the reticulocyte stage until 
mitochondria are lost from the cell (1). In 
circulating erythrocytes protoporphyrin content 
decreases with red cell ageing which is not observed 
in other states in which red cell protoporphyrin is 
increased, such as iron deficiency and lead poisoning 
(32,33). This loss in protoporphyrin occurs because 
the excess protoporphyrin is free and not chelated 
with zinc as in lead poisoning and iron deficiency.
In the latter disorders which are not associated with 
photosensitivity, zinc protoporphyrin is bound to 
haemoglobin and remains in the erythrocyte for as long 
as it circulates. Free protoporphyrin however is 
less easily bound to haemoglobin within the red cell 
and diffuses more easily into plasma (33,34).
9 .
Although ferrochelatase might be deficient in all body 
tissues in EPP patients, it seems as though bone 
marrow reticulocytes are the major source of excess 
protoporphyrin (35) . The hepatic disease may well be 
due to protoporphyrin deposition. Functional 
ferrochelatase deficiency has been demonstrated in 
cultured skin fibroblasts (36) and mitogen stimulated 
lymphocytes of EPP by incubating these cells with ALA 
and measuring protoporphyrin accumulation (37) . In 
cells from EPP patients protoporphyrin accumulation 
from ALA was greater than in normal cells and the 
responses to added iron (36,38) or CaMgEdta (an iron 
chelator) were smaller than in normal cells (37).
These results indicated that ferrochelatase activity 
in EPP was approximately one half of normal, which is 
the level that might be expected for an autosomal 
dominant enzyme deficiency. When ferrochelatase 
activity was measured directly in various tissue 
lysates of EPP patients, activity of 10 - 25 percent 
of normal was reported (27,29,30,31,39). This might 
be due to technical difficulties in measuring the 
mitochondrial enzyme in tissues with low enzyme 
activity. The indirect measurement therefore 
reflects more accurately the functional activity of 
ferrochelatase.
Hepatic porphyrias
Acute attacks occur in four of the hepatic porphyrias;
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acute intermittent porphyria (AIP), porphyria 
variegata (PV), hereditary coproporphyria (HCP) and 
ALA dehydrase deficiency. These attacks are probably 
due to excess production of ALA by the rate limiting 
enzyme ALA synthetase, when it is activated by factors 
like barbiturates or steroids. ALA is an analogue of 
gamma amino butyric acid (GABA), the most potent neuro 
inhibitor of the brain (40,41). ALA has agonistic 
properties, it impairs the re-uptake of GABA into 
presynaptosomes (42) stimulates the action of GABA and 
inhibits the (Na + K)+ dependant ATPase enzyme which 
is vital for nerve condition (40,41). In an acute 
attack, visceral autonomic neuropathy and peripheral 
neuropathy that can progress to total paralysis are' 
especially prominent. An experimental model has been 
produced which suggests another way in which acute 
attacks may develop in the porphyrias. Haem 
depletion can be induced in porphyric rats with 
reduction in tryptophane pyrrolase activity (a haem 
dependant enzyme). This will elevate tryptophane and 
5HT* turnover in the brain and these two compounds may 
bring about some of the neurological disturbances 
found in acute attacks (43).
Acute intermittent porphyria
Generally porphobilinogen deaminase is 50% of normal 
in red cells, liver and fibroblasts of patients that 
suffer from acute intermittent porphyria (AIP)
* 5-hydroxy-tryptamine
(44,45,46). The disease in the quiescent phase is 
generally associated with increased excretion of ALA 
and PBG in the urine. There are no increased 
porphyrins, hence no dermatological manifestations.
The enzyme deficiency is presumably associated with a 
decrease in the rate of haem synthesis with 
de-repression of ALA synthetase and the risk of acute 
attacks.
There are cases described with AIP who had normal red 
cell PBG deaminase levels, although they had increased 
excretion of PBG and ALA in the urine (47). Four 
different types of PBG-deaminase mutations were also 
identified by immunological and enzymatic studies in 
erythrocytes of patients with AIP from 33 unrelated 
families in Finland. This provided evidence for the 
occurrence of genetic heterogeneity at the locus for 
PBG-deaminase (48,49).
Hereditary coproporphyria
Coproporphyrinogen oxidase is deficient in hereditary 
coproporphyria (50,51). It is a rare porphyria first 
described by Goldberg (52) . There is only one 
description of this disease in South Africa (53). 
Coproporphyrin is excreted in urine and stool and 
there are dermatological manifestations, albeit less 
severe than the other types of porphyria with 
dermatological manifestations. This enzyme
12.
deficiency is also associated with a decrease in the 
rate of haem synthesis, consequently increased 
ALA-synthetase activity is found and acute attacks may 
occur (54).
Porphyria cutanea tarda (PCT)
This disease is probably the most common type of 
porphyria seen in Europe and America and is also 
common in the South African black, white and coloured 
populations (55,56,57). The enzyme uroporphyrinogen 
decarboxylase is deficient in this disease (58,59) and 
it is autosomal dominantly inherited. Cutaneous 
photosensitivity is the major symptom, while 
uroporphyrin and 7-carboxylate porphyrin is present in 
the urine in large amounts, with some increase in 
porphyrins in the stool. Deficiency of the enzyme 
alone will not cause PCT since there is a need for a 
further insult i.e. alcohol, iron, oestrogens and 
drugs. A drug which has recently been found to 
induce PCT in familial enzyme deficiency is dioxin
(60) . Another drug which induced an epidemic of PCT 
was hexachlorobenzene and in this situation the 
disease was acquired, known as the Turkish epidemic
(61) .
The entity of hepato erythrohepatic porphyria is 
probably a homozygous deficiency of uroporphyrinogen 
decarboxylase. The condition manifests itself in
13.
childhood, is severe, autosomal recessively inherited 
and not drug induced (62).
Porphyria Variegata
Porphyria variegata (PV) is particularly common among 
South African whites and it is estimated that 3 out of 
every 1000 whites in this country have inherited the 
disease (63,64). Detailed investigations by Dean 
(63,64) indicated that most cases can be traced back 
to an early Dutch Cape settler - Gerrit Janse who 
married Ariaantje Jacobs in Cape Town in 1688. One 
of their four porphyric children (they had eight) 
married Cornells van Rooyen. There are now several 
hundred families with PV in S.A. especially of 
Afrikaans speaking origin and certain names are common 
among them: van Rooyen, van Deventer, Nel, van der 
Vyver, Becker and Lombard (64).
Porphyria variegata does not manifest itself 
clinically or biochemically before puberty.
Cutaneous sensitivity occur in at least 80% of cases 
(65) and increased fragility of sun exposed areas of 
the skin is quite common. Cutaneous lesions are less 
common in patients living in Europe and Northern 
America than in S.A. (66). The dermatological 
manifestations are more common in males and acute 
attacks are more common in females, probably because 
of dieting, hormonal imbalance, menstruation and
14.
infection. They are also more likely to take pills, 
some of which may be potent inducers of an acute 
attack. Over the past decade with the identification 
of most porphyric families and factors known to 
precipitate acute attacks, the incidence of the latter 
has significantly decreased (67). The skin 
manifestations occur on the exposed part. The patient 
complains that the skin is easily abraded and this may 
be the only cutaneous manifestation. A striking 
feature are bullae which may become infected in which 
case scarring is inevitable. Pigmentation and 
hypertrichosis involving particularly the temple areas 
are very common (67). Large amounts of 
protoporphyrin and to a lesser extent coproporphyrin 
is present in the stool (68). There is also 
increased coproporphyrin and uroporphyrin in the 
urine. Day et al., suspected deficiency of 
uroporphyrinogen decarboxylase and coined the name 
Dual Porphyria (69). Abdominal pain and neuropathy 
are the same as in AIP. Acute attacks are mainly 
induced by drugs like barbiturates, sulphonamides and 
oral contraceptives when large amounts of ALA and PBG 
are excreted in urine. Coproporphyrin (mostly type 
III) is often increased as well, and excess 
uroporphyrin may form nonenzymatically from excess PBG 
(65) .
A fifty percent reduction of protoporphyrinogen 
oxidase activity has been found in PV (70, 71, 72).
However variable results have been reported for 
ferrochelatase activity in PV. Becker et al., (39) 
and Viljoen et al., (73) found reduced ferrochelatase
activity in bone marrow, fibroblasts and leucocytes in 
South African cases of PV, while normal activity was 
found in muscle tissue (74). On the other hand 
Brenner and Bloomer, (75) reported normal 
ferrochelatase activity in fibroblasts from PV 
patients while Deybach et al., (72) found 20%
reduction in enzyme activity in peripheral lymphocytes 
in PV patients. When ALA is added to PV fibroblasts, 
protoporphyrinogen does not accumulate and 
protoporphyrin levels increase to the same degree as 
in normal cells, whereas in EPP protoporphyrin 
accumulation in fibroblasts (75) or mitogen stimulated 
lymphocytes with ALA incubation is about twice normal 
(37). Therefore ferrochelatase is clearly limiting 
for ALA metabolism to haem in fibroblasts from normal 
PV or EPP subjects, but a 50% loss of normal activity 
of protoporphyrinogen oxidase does not appear to limit 
ALA metabolism to protoporphyrin in these cells.
This is similar to what has been observed with 
cultured cells from HCP patients with 50% of normal 
activity of coproporphyrinogen oxidase, i.e. there is 
no increased accumulation of protoporphyrin. This 
suggests that factors that induce ALA synthetase in 
the liver but not in other cells such as fibroblsts 
are important in the full expression of disordered 
porphyrin metabolism in PV (1). It is of interest
that even gross enzyme deficiencies along the haem 
biosynthetic pathway e.g. uroporphyrinogen 
decarboxylase deficiency in EHP,are not followed by 
lack of haem formation. The enzyme deficiency 
underlying AIP,PV and HCP is presumably associated 
with a decrease in the rate of haem synthesis and the 
consequent de-repression of ALA-synthetase. When 
there is an increase in the demand for haem, e.g. for 
the synthesis of the enzyme P450 to detoxify 
barbiturates and sulphonamides there is a further 
increase in ALA-synthetase activity with excessive 
formation and excretion of ALA and PBG.
In 1977 in an annotation in the British Journal of 
Haematology, it was suggested that each porphyria 
could be due to a single enzyme deficiency along the 
haem biosynthetic pathway (76). There is now however 
considerable evidence that in several of the 
porphyrias more than one enzyme may be deficient.
The first example described was in AIP where a second 
enzyme defect, that of steroid 4-5 alpha reductase 
was found in some patients (77) . This defect is 
characterised by increased formation of 5 beta 
metabolites (potent inducers of ALA synthetase) from 
natural steroids, testosterone and 11-beta 
hydroxyandost-4-en 3,17 dione. In this way hormonal 
disturbances could induce an acute attack in AIP. Of 
greater interest has been the accumulating clinical 
and biochemical evidence that in PV there might be
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four enzyme deficiencies. In South African cases of 
PV there is evidence for deficiency of PPO (71), 
ferrochelatase (39), uroporphyrinogen decarboxylase 
(Dual Porphyria) (69), and even
uroporphyrinogen-I-synthetase (78). In this regard 
the report by Yamada et al., (79) is of great 
interest. A patient died in an acute attack. The 
porphyrin profile suggested that the patient had PV.
At post-mortem, liver, marrow and sciatic nerve tissue 
were taken and several enzymes along the haem 
biosynthetic pathway studied. Both ferrochelatase and 
uro-l-synthetase were reduced by more that 50% in 
liver and bone marrow and uro-I-syhthetase was also 
reduced in sciatic nerve. In Chester Porphyria which 
appears to be similar to PV,PPO and uro-I-synthetase 
deficiency were described and ferrochelatase activity 
may also be decreased (80) . In South African cases of 
EPP, deficiency of PPO in addition to ferrochelatase 
has been reported (71). The fact that both PPO and 
ferrochelatase might be deficient in EPP and PV is not 
altogether surprising, since these two enzymes, 
responsible for the last two steps in the haem 
biosynthetic pathway, have a similar action and are 
both situated in the inner mitochondrial membrane.
PPO removes six hydrogens from the porphyrin 
ring,while ferrocheltase removes two protons and 
inserts iron into the ring for the formation of heam 
(Fig. 3). While deficiency in both these enzymes 
were described in South African cases of PV and EPP a
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FIG. 3: Conversion of protoporphyrinogen to haem (1).
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different pattern emerged between the decrease in 
ferrochelatase in these two diseases. Becker and 
Viljoen et a_l. (39) found a 50% reduction in 
ferrochelatase activity in sonicated normoblasts and 
fibroblasts of PV patients, whilst in marrow lysates 
of EPP patients ferrochelatase activity was 15% of 
normal. Viljoen et al., (71) reported a 50% decrease
in ferrochelatase in leucocytes of PV patients when 
activity was measured with ferrous sulphate and 
protoporphyrin as substrate in the presence of 
ascorbic acid. However a 65% increase in enzyme 
activity was reported when ferric chloride and 
protoporphyrin was used as substrates (in the presence 
of reduced glutathione). These findings indicated a 
structural change in ferrochelatase from PV patients 
which might be the result of a dominantly inherited 
structural gene mutation. It was suggested that a 
quantitative reduction of ferrochelatase activity is 
present in PV. When erythroid ferrochelatase 
activity was measured at different pH and temperature 
values in EPP and PV patients the the pH activity 
curves were similar. However in PV patients and 
normal subjects the plots of ferrochelatase activity 
vs temperature were monophasic but in EPP they were 
truncated. In addition zinc did not form a zinc 
protoporphyrin complex in fibroblasts from EPP 
patients (81). These results indicated that in EPP 
the genetic mutation results in a variant or unstable 
ferrochelatase. These different ferrochelatase
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patterns in EPP and PV could explain the different 
clinical expression for these diseases.
If both enzymes are deficient in PV and EPP, then 
there is likely to be common subunits or polipeptides 
between them. This thesis was undertaken to (A) 
confirm that these two enzymes are indeed deficient in 
EPP and PV and (B) to purify both enzymes and to 
establish structural and immunological similarities 
between them.
A. Since ferrochelatase activity in fibroblasts and 
most other cultured cells is markedly lower than in 
liver and erythroid precursor cells (27,29) it is 
extremely difficult to assay ferrochelatase activity 
in isolated mitochondrial fractions from non-hepatic 
or non-erythroid cells, the results are difficult to 
reproduce with a wide standard error of the mean for 
controls and it has already been applied to PV and EPP 
cases (71) . However protoporphyrin IX accumulation 
in cultured lymphocytes after a three day 
pre-incubation with mitogens was 10-15 fold greater 
than in cells from the same subjects that were not 
incubated with mitogens (90) . These lymphocytes 
undergo transformation and metabolic activation after 
treatment with the mitogens pokeweed mitogen (PWM) or 
phytohaemagglutinin (PHA). Significant ferrochelatase 
deficiency can be shown indirectly by incubating 
mitogen stimulated lymphocytes with ALA and
determination of protoporphyrin IX synthesised. With 
decreased ferrochelatase activity as in EPP there is 
increased protoporphyrin formation as compared to 
controls (37). It is proposed to measure 
ferrochelatase activity in mitogen stimulated 
lymphocytes from PV patients and their offspring, EPP 
patients and normal subjects, using the indirect 
method (37,90). Furthermore, protoporphyrinogen 
oxidase activity will be measured fluorometrically as 
described by Brenner and Bloomer (82) in untreated 
lymphocytes from these subjects. PPO activity has 
not been measured in prepubertal children before and 
has only been measured in two EPP patients (71).
B. While the early, soluble enzymes in the haem 
biosynthetic pathway have now been studied and 
characterised in several systems (83), the terminal 
membrane bound enzymes protoporphyrinogen oxidase and 
ferrochelatase have been proven difficult to isolate 
and purify partly due to the membrane bound nature of 
these proteins. In fact mammalian ferrochelatase have 
only recently been purified to homogeneity (84,85) 
while PPO has only been partially purified from rat 
liver mitochondria (86) . In order to test the 
hypothesis that there might be structural similarities 
between PPO and ferrochelatase it is proposed to 
isolate and study both enzymes as follows:
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Ferrochelatase will be purified from bovine liver 
mitochondria by the method of Dailey et al., (84) and 
PPO will be purified from the same source using the 
same basic method and anion exchange chromatography 
using a high pressure liquid chromatography apparatus 
as additional purification step. The purity of the 
enzyme will be determined and enzyme kinetics done to 
characterise the enzyme. Monospecific antibodies to 
both of the enzymes will be raised in rabbits and the 
immunological cross-reactivity between ferrochelatase 
and PPO will be tested using the ELISA technique 
(87). Thereafter tryptic peptide analysis of the two 
enzymes will be done by two dimensional chromatography 
according to the method of Elder et al., (88).
CHAPTER 1
MEASUREMENT OF PPO AND FERROCHELATASE
ACTIVITY IN HUMAN LYMPHOCYTES
CHAPTER 1
In the present chapter PPO activity in lymphocytes, 
and protoporphyrin formation by mitogen stimulated 
lymphocytes (incubated with ALA) in the presence of 
CaMgEDTA or iron was measured in EPP and PV patients 
and their offspring. The results suggest deficiency 
of both PPO and ferrochelatase in these diseases.
MATERIALS AND METHODS
Blood was obtained from 18 adult volunteers, 6 
patients with EPP and 12 with PV. Fifteen children 
(mean age 6) from seven PV families were studied. 
Informed consent was obtained from every individual or 
their parents. The porphyrin profile of these cases 
are illustrated in Table 1.
1. Preparation of lymphocytes and cell culture
The method as described by Sassa et al., (37,90)
is illustrated by the flow diagram (Fig. 1) and 
was used as follows: All preparations were 
performed under sterile conditions. 25 ml of 
venous blood was withdrawn from adults and 8 ml 
from children and immediately heparanized with 
10 units of heparin solution (Glaxo (Pty.), Ltd. 
S.A.) per ml of blood.
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TABLE 1
STOOL PORPHYRINS IN PROPOSITI
Family Member
Coproporphyrin 
nmo£./g dry wt 
(0 - 50)
Protoporphyrin 
nmo£/g dry wt 
(0 - 200)
1 Mrs. A 431 758
2 Mrs. H 81 316
3 Mr. G 518 969
Mrs. G 406 797
4 Mr. Le R 66 248
5 Mrs. S 148 581
6 Master V 265 653
7 Mrs. M 87 311
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Heparinized blood was diluted with one volume of 
culture medium (RMPI-1640 medium containing 
streptomycin (0,1 g/1) and penicillin (0,06 g/1) 
(obtained from the National Institute of 
Virology, Rietfontein, S.A.). 8 ml Of diluted
blood was overlayed on a 6 ml Ficoll-paque 
solution (Pharmacia Fine Chemicals AB, Sweden) 
[specific gravity 1,077 + 0,001 g/ml] in a 17 x 
100 mm polystyrene Falcon tube (Falcon plastics, 
Oxnard, USA). The tubes were centrifuged at 
400Xg for 30 min. at room temperature and the 
lymphocyte rich interphase fraction was 
collected and transferred to a 50 ml conical 
centrifuge tube. 30 ml of the medium was added 
and the tubes were centrifuged again at 400Xg 
for 5 min. to sediment the cells. The cell 
pellet was resuspended in 5 ml of the following 
solution: 0,13M NH4C1; 0,017M Tris; 0,01M KHC03 
pH 7,65. It was left to stand for 5 minutes to 
haemolyse contaminating red cells. The cell 
pellet was washed twice (centrifugation at 
200Xg) with 5 ml of culture medium and finally 
suspended in the medium supplemented with 10% 
heat inactivated fetal bovine serum (Flow 
Laboratories, Scotland), 1% (wt/vol) 
phytohaemagglutinin and 1% (wt/vol) pokeweed 
mitogen (Gibco Laboratories, Grand Island
Biological Co., Grand Island, N.Y.). The final
5cell count was adjusted to 5 x 10 cells/ml.
Cells were stained with Turk's stain (0.2 g 
gentian violet/250g glacial acetic acid, 5M) and 
counted on a Neubauer counting chamber. Usually
g+ 2 x 10 cells were obtained from adults and +
g0,5 x 10 from children. The cell suspension 
was transferred into 12 x 100mm Falcon tubes (1 
ml/tube) and incubated at 37 degrees C for 72 
hours in an atmosphere of 5% C02 and 100% 
relative humidity. Incubation time of 
lymphocytes with mitogens and optimal lymphocyte 
and mitogen concentrations for optimal 
stimulation of lymphocytes have previously been 
determined (90,38).
As excess protoporphyrin and coproporphyrin are 
only found in PV subjects after puberty, 
lymphocytes from children who were suspected to 
have a propensity for the disease, i.e. low PPO 
activity (Chapter 2) were incubated with 
steroids to see if hormones had any effect on 
protoporphyrin synthesis (90) . 17B-oestradiol 
and testosterone (4 ug/ml) were added 
respectively to additional vials containing 
lymphocytes from PV children with reduced PPO 
activity (stock solutions of 1 mg/ml of the 
hormones were prepared in ethanol) (90). For 
the protoporphyrinogen oxidase assay, cells were 
suspended in culture medium supplemented with 
10% heat inactivated fetal bovine serum and kept 
overnight on ice.
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2. Incubation of stimulated lymphoytes with ALA
Each experiment included one or two PV subjects, 
one EPP subject and a normal control.
Experiments were repeated two to three times on 
each PV and EPP subject. The coefficient of 
variation for PV patients was 11% and ~ 6% for 
EPP patients. After 3 days of incubation in 
the presence of mitogens, the cells were 
centrifuged at 200Xg and washed twice with 1 ml 
of serum free F-l medium supplemented with 
crystalline insulin (1 ug/ml). This medium 
(devoid of serum and phenol red) was earlier 
found to be more effective than a serum 
containing medium in supporting the formation of 
porphyrins and inhibiting release of porphyrins 
into growth medium from cultured skin 
fibroblasts (92) . These findings were 
confirmed in human lymphocytes (37) . Cells 
were suspended in Fl-medium (prepared by Flow 
Laboratories, Scotland), containing 0,6 mM ALA 
(Sigma, St. Louis, USA) with or without 5 mM 
CaMgEDTA or 25 uM ferrous ammonium sulfate, and 
then incubated for 24 h at 37 degrees C in 5%
CO2 atmosphere. Concentrations of ALA, CaMgEDTA 
and ferrous ammonium sulphate have previously 
been optimised for this experiment (90,38). Each 
experiment was carried out in quadruplicate, 
which had a coefficient of variation of ~ 4%.
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CaMgEDTA is a potent iron chelator and inhibits 
ferrochelatase in cultured cells since iron is a 
substrate for the enzyme. This inhibitor does 
not however, interfere with the cellular balance 
of calcium and magnesium which, if it occurred, 
would interfere with the viability of the cells 
(11) .
2.1 Preparation of CaMgEDTA 0,1M (91)
Deionised and distilled water was used for 
preparing solutions.
2.1.1 4,38g EDTA plus 2,8g NaOH was dissolved 
in 100 ml H 2 O.
2.1.2 2,2 g CaC^ 1^0 and 3,05 g MgC^ GH^O was 
dissolved in 40 ml H2 0 in a separate 
flask.
2.1.3 The salt solution was added slowly to the 
EDTA solution. When the pH dropped below 
6,0, strong NaOH was slowly added. Care 
was taken not to exceed pH 9,0, as above 
pH 9,0 the hydroxides precipitate.
2.1.4 The pH was adjusted to 7,0 with either
dilute HC1 or NaOH.
2.1.5 The volume was adjusted to 150 ml.
2.2 Measurement of protoporphyrin formation
After incubation with ALA for 24 hours, 
cells were harvested by centrifuation at 600 
g for 5 min. 500 ul Of a 0,5 M perchloric 
acid-50% methanol solution was added to the 
cell pellet and the tube was vortexed for 30 
sec. This mixture was centrifuged at 600 g 
for 5 min. and the supernate was transferred 
to a 500 ul microcuvette. The fluorescence 
was determined at excitation wavelength 405 
nm and emission 630 nm on a Perkin Elmer 203 
fluorescence spectrophotometer.
7Protoporphyrin IX disodium salt (1 x 10- M) 
(Sigma) dissolved in the perchloric acid 
methanol solution was used as a standard.
Protein determination
Protein concentrations were determined by the 
method of Lowry et al., (94) with crystalline
bovine albumin as standard (Chapter 3). The 
measurements were made on the cellular 
precipitate in the tissue culture tubes as well 
as on 10 ul aliquots from the cell sonicates.
The cellular precipitate was dissolved in 500 ul
0,2 M NaOH and heated at 60 degrees C for 30 
min. for solubilization.
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RESULTS
Ferrochelatase activity
Protoporphyrin synthesis by mitogen stimulated 
lymphocytes incubated with ALA was linear with time 
(Fig. 2).
When stimulated lymphocytes from normal subjects were 
incubated with ALA for 24 hours, 785 pmol 
protoporphyrin/mg prot. (range 654-966) was formed 
(Fig. 3) with a 1.78-fold increase in the presence of 
CaMgEDTA (Fig. 4). When incubated with ALA, 
stimulated lymphocytes from four EPP subjects formed: 
mean 1035 pmol protoporphyrin/mg prot. (range 
954-1102) (Fig. 3), approximately 1.3-fold more than 
normal lymphocytes, with a 1.1-fold increase in the 
presence of CaMgEDTA (Fig. 4). On the other hand, 
stimulated lymphocytes from five PV subjects 
accumulated: mean 1188 (range 703-1476) pmol 
protoporphyrin (Fig. 3), 1.5-fold more than observed 
in normal lymphocytes, with a 1.36-fold rise in the 
presence of CaMgEDTA (Fig. 4). There was a smaller 
increase in protoporphyrin accumulation by these cells 
on the addition of CaMgEDTA compared to controls but a 
larger increase compared to EPP lymphocytes under the 
same conditions. In this group (PV), stimulated 
lymphocytes from one subject accumulated normal 
amounts of protoporphyrin (o) (Fig. 3). Mitogen
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FIG. 2 Protoporphyrin formation by stimulated 
lymphocytes incubated with ALA over time.
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FIG. 3: Effect of ALA on protoporphyrin IX formation
FIG. 4 Effect of CaMgEDTA on protoporphyrin IX 
formation. Data were expressed as the 
ratio of protoporphyrin IX formed with the 
treatment of CaMgEDTA plus ALA to that 
formed with ALA alone. (o) Represents the 
patient described in the text.
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stimulated lymphocytes from PV offspring with normal 
PPO activity as well as PV offspring with reduced PPO 
activity accumulated normal amounts of protoporphyrin, 
mean: 750 (range 599-961) and (range 546-925)
(Fig.3). With approximately a 1.7-fold increase in 
the presence of CaMgEDTA (Fig. 4). The effect of iron 
on mitogen stimulated lymphocytes incubated with ALA 
and iron is shown in Figs. 5 and 6. When lymphocytes 
of normal adults were incubated with iron and ALA, 129 
pmol protoporphyrin/mg prot. (range 58-221) 
accumulated, an 83% reduction in protoporphyrin 
accumulation. When EPP lymphocytes were treated 
similarly, protoporphyrin accumulation was reduced by 
only 40%: mean 557 pmol/mg prot. (range 412-769).
The effect of iron on stimulated lymphocytes of four 
PV patients who showed elevated protoporphyrin levels 
when incubated with ALA was also studied. In the 
presence of iron 335 pmol protoporphyrin (mean) 
accumulated (range 272-368), a 70% reduction in 
protoporphyrin accumulation by their lymphocytes.
There was a significant difference in the ratio of 
protoporphyrin accumulation by PV lymphocytes 
incubated with ALA and iron to that formed with ALA 
alone as compared to the same ratio in normal 
lymphocytes (Fig. 6) (P<0.05). The difference in this
ratio was even more marked between normal and EPP 
lymphocytes (Fig. 6) (P<0.001). Stimulated
lymphocytes of PV offspring with reduced or normal PPO 
activity behaved like normal adult lymphocytes when 
incubated with iron and ALA. *
* Statistical probability
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FIG. 5: Effect of iron on protoporphyrin IX
formation.
FIG. 6 Ratio of protoporphyrin IX formed with the
treatment of iron plus ALA to that formed
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with ALA alone
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There was no difference in protoporphyrin synthesis 
when hormones (oestrogen or testosterone) were added 
to the lymphocytes from children with reduced PPO 
activity and incubated with ALA (results not 
included). The hormonal profile of the one PV 
patient whose stimulated lymphocytes synthesized 
normal amounts of protoporphyrin and who previously 
was found to have normal ferrochelatase, was normal.
4. Measurement of protoporphyrinogen oxidase
activity
Lymphocytes were prepared as described in 
section (1) and kept overnight on ice. PPO 
activity was measured in duplicate by means of a 
fluorometric assay (see below) as described by 
Brenner and Bloomer (82), but with modifications 
in the volume of the assay.
VP, EPP and control samples were assayed in the 
same batch. The lymphocytes were washed twice 
with phosphate buffered saline pH 7,4, 
resuspended in 0,02 M Tris HC1 (pH 8,7) 
containing 2% Tween 20 (v/v) and sonicated three 
times at 50 W/s for 20 sec.
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4.1 Preparation of protoporphyrinogen
A stock solution of 1 mM protoporphyrin 
(Porphyrin products, Logan, Utah, USA), 
dissolved in 0,01 M KOH containing 20% 
ethanol (v/v) was diluted to 200 uM with 
ethanol/KOH. Sodium amalgam (3%) was 
freshly prepared prior to use, by the 
addition of 0,4 g Na to 9,6 Hg and heating 
it under nitrogen (93) . The hot amalgam 
was cooled to room temperature and 
pulverized with a mortar and pestle to a 
fine sand. It was then transferred in the 
dark under nitrogen to a flask containing 
the protoporphyrin solution. The 
concentration of sodium amalgam was 2 g/ml 
of protoporphyrin solution. The flask was 
stoppered under nitrogen and shaken until 
the fluorescence under ultraviolet light had 
disappeared (approximately 2-3 min). The 
solution was then filtered in the dark under 
nitrogen through a fine scintered glass 
filter by vacuum. The solution of 
protoporphyrinogen was adjusted to pH 8 with 
40% (v/v) phosphoric acid. After standing 
in the air in the dark overnight, 50-70% of 
the protoporphyrinogen reoxidized to 
protoporphyrin.
39.
4.2 Assay of protoporphyrinogen oxidase 
activity
Previous studies demonstrated that the 
activity of PPO was greater at pH 8,7 than 
at physiological pH in sonicates of human 
fibroblasts (82) as well as lymphocytes 
(72). Therefore all assays were performed 
at pH 8,7. The reaction mixture (500 ul) 
consisted of 5 mM glutathione, 1 mM EDTA,
100 mM Tris HC1 (pH 8,7), Tween 20, 1% (v/v) 
and 50 uM protoporphyrinogen with the cell 
sonicate. A reagent blank, non-enzymatic 
control, and protoporphyrin standard were 
also prepared. The reagent blank consisted 
of the standard reaction mixture except that 
0,01 M KOH/20% ethanol was substituted for 
the protoporphyrinogen solution. In the 
non-enzymatic control, the tissue 
preparation was first heated at 75 degrees C 
for 15 min. In the protoporphyrin standard, 
5 uM protoporphyrin was substituted for the 
protoporphyrinogen. The assay was started 
by adding the protoporphyrinogen to the 
untreated tissue preparation and the 
non-enzymatic control.Each flask was 
incubated at 37 degrees C in the dark in 
room air without shaking. This was done to 
minimize the non-enzymatic formation of
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protoporphyrin from protoporphyrinogen. 
Periodically 20 ul of reaction mixture was 
added to 480 ul of a mixture consisting of 5 
mM glutathione, 1 mM EDTA and 100 mM Tris 
HC1 pH 8,7. The fluorescence emission at 
635 nm was measured in microcuvettes with a 
Perkin Elmer 203 spectrofluorometer at 
excitation wavelength 405 nm.
RESULTS
B. Protoporphyrinogen oxidase activity
Protophyrinogen oxidase activity is expressed as nmol 
protoporphyrin formed per hour per mg protein. 
Porphyrin generated by the viable tissue preparation 
and heat treated control had the same flourescense 
spectra as the protoporphyrin standard. Thus, when 
protoporphyrin was reduced to protoporphyrinogen by 
amalgam and reoxidized either enzymatically or 
non-enzymatically, the only porphyrin generated was 
protoporphyrin. Tween 20 enhanced the fluorescence 
of protoporphyrin presumably because protoporphyrin 
was maintained in its monomeric form. Tween 20 also 
minimized the effect of different amounts of tissue 
(82). Glutathione (reduced) inhibited auto-oxidation 
of protoporphyrinogen in the assay mixture (86). 
Substrate concentration of 50 uM was saturating for 
the enzyme in sonicated lymphocytes (Fig. 7). From 
this graph a Km value of 25 uM is obtained using the
formula:
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FIG. 7; Effect of substrate concentration on
protoporphyrin formation. Values are 
expressed as fluorescent units produced by 
the active enzyme preparation minus that of 
the heat inactivated control per hour.
Fifty fluorescent units represents a full 
scale deflection on a Perkin Elmer 
spectrofluorimeter at 11.0 sensitivity.
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V = Vmax[S] ; if V 1/2 Vmax; then Vmax = Vmax[S]
Km + [S] 2 Km + [S]
Km + [S] = 2[S]
Km = [S] (95) .
When a Lineweaver Burk plot is drawn from these values 
the Km obtained is 100 uM. This value might not be 
valid since there are only 3 points on the linear 
region of the curve, while inhibition was found at 
high substrate concentrations. A substrate 
concentration of 50 uM was also saturating for human 
fibroblasts (82). Using this concentration of 
substrate, the mean level of PPO activity was 6,82 
nmol protoporphyrin/mg prot/hour, which was similar to 
the value found by Deybach et al., (72).
There was an initial lag period in the generation of 
protoporphyrin both by the active as well as heat 
inactivated enzyme preparation (Fig. 8). The 
generation of protoporphyrin was linear with time 
after the lag period and PPO activity was measured 
during the linear time period. Protoporphyrin 
formation by the active enzyme reached a plateau after 
approximately two hours, while protoporphyrin 
formation of the control remained linear with time 
(Fig. 8). The difference between the rate of 
enzymatic protoporphyrin generation and non-enzymatic 
protoporphyrin generation measured PPO activity.
FIG. 8: PPO-activity over time: (--- ), Product
formed by heat-inactivated lymphocyte 
control. (_____), Product formed by active
lymphocyte preparation.
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Non-enzymatic protoporphyrin formation was usually 30 
- 40% of total enzymatic protoporphyrin formation. 
Protoporphyrin formation was linear up to 1,25 mg of 
lymphocyte protein (Fig. 9). Protein concentrations 
used ranged from 0,2 to 0,5 mg per assay mixture.
The assay precision within a batch was ~ 11%.
PPO activity was reduced by 41% in 11 patients with PV 
as compared to normal individuals: mean 4.0 nmol 
protoporphyrin/mg prot/h (range 2.6-5.3) versus 6.8 
(6.3-7.7) (P<0.001) Table 2. In five cases of EPP,
PPO activity was reduced by 35%, mean 4.4 (range 
3.0-5.0) (PC0.001). PPO activity was determined in 15
children from PV families. Using the student's 
t-test to compare PPO activity from each offspring 
with the mean activity of normal adults, eight 
children seemed to have normal levels of PPO, while in 
seven children PPO activity was reduced by 40% : mean 
7.2 (range 6.4-8.4) versus 4.3 (2.6-5.2) (PC0.001)
(Table 2).
DISCUSSION
PV fibroblasts incubated with ALA by Brenner and 
Bloomer (75), accumulated the same amount of 
protoporphyrin as did normal fibroblasts.
They had reduced PPO activity and normal 
ferrochelatase activity when these enzymes were 
assayed directly. The lymphocytes from our PV 
offspring with normal or reduced PPO activity showed
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FIG. 9: Effect of protein concentration on
protoporphyrin formation: (--- ), Product
formed by heat-inactivated control. (___
), Product formed by active lymphocyte 
preparation.
46
TABLE 2
PROTOPORPHYRINOGEN OXIDASE ACTIVITY IN LYMPHOCYTES 
(nmol/mg/protein/hr.)
Normal
subjects
PV
Patients
EPP
Patients
PV offspring 
with normal 
PPO
PV offspring 
with reduced 
PPO
6,60 3,39 4,50 7,17 2,63
7,24 2,56 4,55 8,40 4,50
6,60 4,80 4,75 6,80 4,61
7,10 4,38 2,98 6,36 5,25
7,69 4,61 5,04 6,80 3,50
6,22 2,04 7,65 5,20
6,55 5,26 6,57 4,32
6,70 4,50 7,80
6,87 4,60
7,22 4,10
6,74 4,02
6,30
Mean 6,82 4,02 4,36 7,19 4,33
SEM*+0,123 +0,296 +0,359 +0,247 +0,331
By using the t-test (statistical significance test) to compare the 
PPO-activity from each PV-offspring with the mean activity of the 
normal adults, the children could be separated into two groups; 
one group with reduced PPO-activity and the other group with normal 
PPO-activity.
* Standard error of the mean
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normal protoporphyrin accumulation when stimulated 
with mitogens and incubated with ALA, alone or with 
the addition of chelators or iron and it is inferred 
that ferrochelatase is not reduced in those PV 
offspring with reduced PPO activity. By contrast, 
there was a marked increase in protoporphyrin 
accumulated in mitogen stimulated lymphocytes 
incubated with ALA from four out of five PV patients 
with reduced PPO activity. This is not surprising 
since reduced ferrochelatase activity has been 
reported previously in their leucocytes (71). The 
findings in case (o) are of particular interest.
She has reduced PPO activity and normal accumulation 
of protoporphyrin when her mitogen stimulated 
lymphocytes were incubated with ALA. She was the 
only patient in a previous study (Viljoen et al., (71)
case 10) who had normal ferrochelatase activity when 
estimated by two different methods. This supports 
the theme that increased protoporphyrin accumulation 
by mitogen stimulated lymphocytes incubated with ALA 
reflects decreased ferrochelatase activity and is not 
altered by reduced PPO activity alone. The results 
were interpreted as follows: In children from PV
families, reduced PPO activity may reflect the PV 
trait but their ferrochelatase is normal. In adult PV 
patients both PPO and ferrochelatase activity may be 
reduced. Although PV becomes clinically and 
biochemically manifest after puberty, it was not 
possible to show that the decrease in ferrochelatase
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activity after puberty, was due to hormones (oestrogen 
and testosterone).
There was a 36% reduction in PPO activity in EPP 
lymphocytes. This was not due to inhibition of 
protoporphyrinogen oxidase by protoporphyrin.Trace 
amounts only of protoporphyrin were present in EPP or 
PV lymphocytes before these cells were stimulated with 
mitogens. Since it has repeatedly been shown that 
ferrochelatase is reduced in EPP it would appear, 
therefore, that both PPO and ferrochelatase are 
decreased in EPP and PV. However, these two diseases 
are clinically and biochemically distinct. Tissue 
specificity (i.e. EPP is primarily a disorder in 
erythroid tissue whereas PV is an hepatic porphyria) 
may explain the different clinical expressions of 
these diseases but there must also be an enzymatic 
difference between them. There is no statistically 
significant difference in PPO activity between EPP and 
PV lymphocytes. There are however, distinct 
differences between ferrochelatase activity in EPP and 
PV, as has been outlined in the discussion section of 
this thesis.
A further difference is the finding of a higher level 
of protoporphyrin accumulation in mitogen stimulated 
PV lymphocytes when incubated with ALA than in EPP 
(Fig. 3). There was a further 37% increase on the 
addition of CaMgEDTA to the PV cultures, whereas the
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rise of protoporphyrin in mitogen stimulated EPP 
lymphocytes incubated with ALA and CaMgEDTA was only 
14%. When stimulated lymphocytes from normal subjects 
were incubated with ALA and iron there was an 83% 
decrease in protoporphyrin accumulation; compared with 
a 70% decrease in cases of PV and 43% decrease in 
those from EPP subjects. It is of great interest 
that there was a 50% decrease in ferrochelatase 
activity by EPP stimulated lymphocytes when the 
difference between protoporphyrin formation from ALA 
by replete (+iron) and iron deficient (+CaMgEDTA) 
cells is compared to normal stimulated lymphocytes 
treated similarly. However, there was no difference 
in protoporphyrin formation by iron replete and iron 
deficient stimulated lymphocyte from PV patients 
compared to controls; yet PV stimulated lymphocytes 
incubated with ALA alone; ALA +iron and ALA + CaMgEDTA 
accumulated increased protoporphyrin as compared to 
normal lymphocytes. This would suggest that the 
disturbance in ferrochelatase in PV is a change in 
enzyme affinity for the substrate iron whereas in EPP, 
ferrochelatase activity is reduced. It is suggested 
that in EPP the defect in ferrochelatase is primarily 
in the red cell and that a different disturbance in 
ferrochelatase which is present in the liver accounts 
for the different clinical and biochemical 
manifestations of these diseases. The present 
results demonstrate a further difference in 
ferrochelatase characteristics between PV and EPP.
CHAPTER 2
PROTOPORPHYRINOGEN OXIDASE ACTIVITY IN
SEVEN FAMILIES WITH PORPHYRIA VARIEGATA
CHAPTER 2
Porphyria variegata (PV) is a disease which manifests
itself both clinically and biochemically after
puberty. Children from PV families have no clinical
features of the disease and their stools are negative
for porphyrins. In 80% of adult cases there are
dermatological features but few show severe lesions
and acute attacks are rare (96). The diagnosis of PV
in adults is established when excess copro-and
protoporphyrins are found in the stool even in the
quiescent phase of the disease (68), however, a normal
value is occasionally found in a probable carrier.
High excretion of porphyrins in the stool has been
reported in cases of carcinoma (97). It is possible
that more sophisticated techniques such as TLC+and 
*HPLC used on stool samples (98) and plasma porphyrins 
measured either chromatographically (99) or by the 
fluorescence emmision spectra (100) may identify more 
adults with PV. It is however doubtful if any of 
these techniques will identify those children in PV 
families who carry the gene (Pp) and for this reason 
it is essential to measure the enzyme defect. This 
chapter deals with the findings regarding 
protoporphyrinogen oxidase (PPO) activity in seven PV 
families. It may now be possible to identify PV 
carriers and their offspring before puberty, who at 
puberty will develop into overt cases of PV. *
+ Thin layer chromatography* High pressure liquid chromatography
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MATERIALS AND METHODS
Blood and stool samples were collected from 7 PV 
families. In all, 16 adults; (in one family there 
were three generations), and 16 children were 
studied. The age of the children ranged from 6 - 1 3  
years. The sexes were equal in numbers. Stools 
were analysed for porphyrins by the method of 
Rimington (101) and PPO was measured in leucocytes as 
described in,Chapter 1.
RESULTS
Family 1: Mrs. A. aged 30 years had porphyric skin 
lesions on the hands for 9 years. Her paternal 
grandmother was a Van Rooyen. Occasionally her urine 
had been dark but she has had no acute attacks. Her 
stools were always strongly positive for porphyrins 
(Table 1; Chapter 1). She had 2 children, a daughter 
aged 11 and a son aged 7 years. Porphyrins were 
absent from their stools. PPO activity of Mr. and 
Mrs.A. and their two children were as follows:
2-63
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Male subjects with PV are represented by hatched 
squares and females by hatched circles. Normal 
members are denoted by open symbols. PPO activity is 
expressed as nmol protoporphyrin synthesised per hour 
per mg protein
Conclusion: The son carries the gene for PV.
Family 2: Mrs. H.aged 34 years presented with 
porphyric skin lesions on the hands at the age of 
20. The diagnosis was established in 1978 on both 
skin biopsy and the finding of excess porphyrin in her 
stool (Table 1; Chapter 1). At that time she was on 
Minovlar, a combined oral contraceptive which was 
immediately stopped. Active skin lesions persisted 
with occasional abdominal pain and a dark urine. She 
also suffered from depression. Her PPO activity and 
that of her husband and two children aged 6 and 7 
years were as follows:
7-29
6-8
Conclusion: Neither child carries the PV gene.
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Farni_1_Y_Ji: T^e parents, both of whom had PV, have been 
described previously (89) (Table 1; Chapter 1). Mrs. 
G. had skin lesions and Mr.G.had both skin lesions and 
acute attacks. Both had raised levels of porphyrins 
in their stools (Table 1). There were no excess 
porphyrins present in the stools of their children 
aged 6 and 8 years. The PPO activities in this family 
were as follows:
Conclusion: Only the son carries the PV gene.
Family 4: Mr. R. aged 37 years (a known porphyric 
with positive stools) (Table 1; Chapterl), presented 
with ill described abdominal pains, never severe, and 
all investigations were negative except that he had a 
hiatus hernia. Since his urine was always negative 
for porphobilinogen the abdominal pain was ascribed to 
the hiatus hernia. The results of PPO activity in 
this family including the parents of the propositus
were as follows:
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Conclusion: The propositus, his father and a
son all appear to carry the PV gene. Mr. R.'s 
father was suspected to have PV as his sibling 
suffered from PV.
Family 5: Mrs. S., whose mother suffered from 
porphyria variegata, presented at the age of 23 years 
with mild porphyric skin lesions. The stools of Mrs.
S. were positive for porphyrins (Table 1; Chapter 1). 
In 1971 and again in 1973 she had acute attacks with 
abdominal pain, pain in her legs, vomiting tachycardia 
and mild hypertension and a port wine coloured 
urine. Urinary porphobilinogen was markedly raised. 
She had a further attack in 1976 while pregnant. On 
each occasion she was treated with phenothiazine 
(Stelazine) a beta adrenergic blocking agent 
(Propanolol) and Hycal. In 1977 she had an episode 
of post partum depression but no further problems. A 
second pregnancy in 1979 was uneventful. Her PPO 
oxidase activity and those of her husband and two
children were as follows:
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Conclusion: Both children carries the PV
genes.
Family 6: The propositus, Master V now aged 12 years 
was first seen in 1977 at the age of 5 years. He was 
atypical, as he had hypoglycaemic convulsions from 
birth. A pancreatectomy was done when he was 3 and a 
half years old. He continued to have fits and was 
treated with phenobarbitone and diphenylhydantoin. At 
the age of 5 he developed porphyric skin lesions of 
the hands and face (stool porphyrins, Table 1; Chapter 
1). He also had acute attacks with abdominal pain, 
vomiting, weakness, and a red urine with excess 
porphobilinogen and delta amino laevulinic acid. His 
PPO activity and that of his brother and parents are 
as follows:
6-7
3-5
4-1
7-65
Conclusion: The propositus had apparently
inherited the disease from his father. The 
propositus' stools were always negative for 
porphyrins; but there was a family history of 
porphyria
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Family 7: Mrs. M. aged 34 years had porphyric skin 
lesions of her hands since the age of 12 years. There 
were blisters between her fingers, her skin abraded 
easily and there were many bullae on the dorsum of her 
hands. After the birth of her first child she took 
oral contraceptives, these exacerbated the skin 
lesions and she developed a lesion on her face. Her 
stool showed raised porphyrin levels (Table 1; Chapter 
1) .
In 1982 she had a bout of abdominal pain but the urine 
did not change colour. Her PPO activity and that of 
her husband and two children were as follows:
Conclusion: Both their children carry the PV
genes. Their stools were negative for 
porphyrins.
DISCUSSION
In recent years protoporphyrinogen oxidase and 
ferrochelatase have been found to be deficient in 
porphyria variegata. However, there were 
discrepancies about the level of ferrochelatase
5 8 .
activity in PV. The method generally used to measure 
ferrochelatase activity is tedious and takes 4 days to 
complete. The results are difficult to reproduce 
with a wide scatter for controls and only one case and 
a control can be studied simultaneously. It is 
therefore not suitable for family studies. Of 
greater importance in this regard was our finding that 
ferrochelatase is normal in children of PV families 
(Chapter 1). The deficiency is only manifested after 
puberty. For these reasons ferrochelatase is not 
suitable for family studies, where the children are 
prepubertal.
The method used to measure PPO activity is relatively 
simple, reproducable and can be measured in 
leucocytes. At least 4 cases and a control can be 
studied simultaneously in two days. Therefore this 
enzyme is clearly more suitable for genetic studies.
As no single large family was available, we elected to 
study 7 families with PV.
Quantitative stool porphyrins were positive in all 8 
propositi. Stools were negative in the fathers of the 
propositi in families 4 and 6, who were suspected on 
family history to carry the PV trait. In all 8 
propositi PPO activity (nm/mg/prot/hr) was reduced by 
an average of ~ 50% (mean 3.7 range 2.04-4.8) as 
compared to controls (mean 6.45 range 5.7 - 7.29).
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There was no overlap between the patients and the 
controls but the number of people studied was small. 
The 2 suspected carriers mentioned above had reduced 
PPO activity (5.4 and 4.1 nmoles respectively). 
Sixteen prepubertal offspring were studied, in all of 
whom stools were negative for porphyrins. In 8 cases 
the PPO activity was reduced by “ 50%. Both sexes 
were equally affected. The results are in keeping 
with the concept that PV is inherited as an autosomal 
dominant disease.
The finding of reduced PPO activity in all PV cases, 
in 2 suspected carriers with negative stools and in 
50% of their offspring does suggest that reduced PPO 
activity is a reliable method for identifying most if 
not all cases of PV and their offspring who could 
evolve at puberty into PV. Unlike
uro-porphyrinogen-l-synthetase in AIP (90) there was 
no overlap between controls and patients but the 
series was too small to be definitive.
It must however be pointed out that reduced PPO 
activity has also been found in (EPP) (71, Chapter 1) 
and the enzyme has not been measured in another 
porphyria or haematological disorder. In lead 
poisoning in particular where there is decreased 
activity of several enzymes along the haem 
biosynthetic pathway (including ferrochelatase) with 
raised red cell protoporphyrin, reduced PPO activity
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may also be found. Whilst reduced PPO activity is a 
good marker for PV cases, suspected carriers and their 
offspring who may develop PV at puberty, it is not 
specific. In particular when EPP is suspected, red 
cell and stool porphyrins must also be measured.
TABLE 1 COMPOSITE TABLE OF 7 PV FAMILIES
Mating No of Families 
observed
Offspring
'
nn Pp PP
nn x Pp 6 7 7
Pp x Pp 1
1
1
Where nn = non porphyria subject
Pp = Heterozygous propositi with porphyria 
and
their offspring with +- 50% reduced PPO 
activity.
PP = Homozygous state of PV.
CHAPTER 3
PURIFICATION OF FERROCHELATASE
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CHAPTER 3
Ferrochelatase (EC 4.99.1.1)
The terminal step in the haem biosynthetic pathway is 
the removal of two protons from and the insertion of 
iron into protoporphyrin to form haem. The enzyme 
ferrochelatase which catalyses this reaction has been 
detected in a wide variety of tissues and organisms 
and in all cases the activity has been associated with 
the mitochondrial membrane fraction. The insertion of 
iron into protoporphyrin can also take place in the 
absence of enzyme under certain conditions (102,103). 
In eukaryotes ferrochelatase is bound to the inner 
mitochiondrial membrane (104,105,106). It has been 
demonstrated that in bovine liver mitochondria, the 
active site for ferrochelatase is located on the 
matrix side of the inner mitochondrial membrane, while 
physically the enzyme spans the membrane with portions 
of the protein exposed on both sides of the membrane
(107) . In plants, activity is found in chloroplasts
(108) while in bacteria the enzyme is bound to the 
cytoplasmic membrane (109,110). Ferrochelatase 
utilizes protoporphyrin IX and other 2- carboxylate 
porphyrins, e.g. deutero-and mesoporphyrin as 
substrates in vitro (104,111,112). It also catalyses 
the insertion of Co^+,Zn^+ and Fe^+ into 
protoporphyrin IX; in fact Co^+ and Zn^+, are more
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efficient enzyme substrates than Fe^ + (113).
Ferrochelatase will not insert Mg^+ or ferric iron
(Fe^+) into protoporphyrin IX (108,109,110,114,115).
Various rates of activity are found depending on the
metal and porphyrin substrates used (111). In human
liver mitochondria, endogenous Zn^ + lowers the rate of
which ferrochelatase is able to add iron to protoporphyrin
2 +because of the enzyme's higher affinity for Zn (116).
Ferrochelatase has been purified to apparent 
homogeneity from a photosynthetic bacterium 
Rhodopseudomonas sphaeroides (117), chicken erythrocytes 
(118), rat liver (119) and bovine liver (120, 84).
Bovine ferrochelatase has a molecular weight of 42,500 
as determined by SDS-gel electrophoresis and an 
apparent molecular weight of 200,000 as determined by 
gel filtration chromatography (Taketani et al., (120). 
Dailey et al., (84) however reported a molecular 
weight of 42,000 as determined by gel filtration 
chromatography indicating that the enzyme is a monomer 
under non-denaturing conditions. The pH optimum of 
the bovine enzyme reaction is pH 8 and mesoporphyrin 
and deuteroporphyrin are more active substrates than 
protoporphyrin (84). Enzyme activity with Fe^+as
substrate is inhibi-ted by metals such as Zn, Co, Cu or
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Mn and it is also inhibited by the end product, 
hemin. Phospholipids and fatty acids markedly 
stimulate chicken erythrocyte ferrochelatase (118) and 
are essential for rat ferrochelatase activity (119), 
although no stimulation was observed with bacterial 
enzyme (117) . Added lipids stimulate bovine 
ferrochelatase only slightly. This might be explained 
by the fact that endogenous lipid or exogenous 
detergent might be bound by the isolated enzyme in a 
way which could mask any stimulatory effects of added 
lipid (84) . Apparently detergents or phospholipids 
facilitate the solubilization of otherwise poorly 
soluble protoporphyrin and provide a similar 
environment as in the membrane for the enzyme to act 
under optimal conditions.
Two divalent cations, Hg2+ and Pb2 + were found to be 
strongly inhibitory, possibly due to their ability to 
interact with free sulfhydryl groups. Activity is 
also inhibited by sulfhydryl reactive compounds such 
as iodoacetamide and N-ethyl-maleimide. Reducing 
agents including glutathione, cysteine and 
dithiothreitol are indispensible in the ferrochelatase 
assay (84,117,120). It is believed that these 
reagents not only reduce ferric iron and maintain 
ferrous iron in the reduced state, but also protect 
the enzyme against auto-oxidation. It would appear 
that ferrochelatase contains sulfhydryl groups 
essential for enzymic activity. For instance reaction
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with [3H]-N-ethyl maleimide indicates that 
modification of a single sulfhydryl group is 
sufficient to inactivate ferrochelatase. It is 
protected from this inactivation by one substrate, 
ferrous iron, but not by the porphyrin substrate, 
indicating that ferrous iron binds to the sulfhydryl 
groups (121). From this observation as well as 
previous findings, i.e. the initial event in the 
enzyme reaction being iron binding, whereupon 
protoporphyrin binds and then haem is released prior 
to proton release (84), Dailey constructed an 
interesting model for the complete enzymic reaction: 
Iron binding to the enzyme is mediated through vicinyl 
sulfhydryl groups whereupon protoporphyrin binds and 
the two hydrogen protons of the porphyrin exchange for 
the molecule of ferrous iron, thus leaving the two 
released protons to associate with two cysteines which 
had previously bound the iron (Fig.l). However, this 
still leaves the question of the fate of the two 
protons that have to be released by the enzyme for the 
next iron molecule to be bound, unanswered. No 
chromophoric cofactors which could accommodate these 
protons were detected by visible spectral analysis of 
the purified enzyme preparation (84,119).
This chapter deals with the purification of bovine 
ferrochelatase according to the method used by Dailey 
and Fleming (84).
FIG. 1; Model for the active site of ferrochelatase 
and the role of sulfhydryl groups. PP is 
protoporphyrin and the porphyrin ring is 
shown as a planar square for diagrammatic 
• simplification
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MATERIALS AND METHODS
1. Purification of ferrochelatase
All reagents and chemicals used were of the highest 
purity available. Buffers containing the following 
reagents were prepared in one liter of distilled and 
deionised water:
Buffer I (pH 8,1) 
0,25 M sucrose 
10 mM Tris-acetate 
1 mM EDTA
Buffer C (pH 8,1) 
20 mM Tris-acetate 
1 mM DTT 
10 ug/ml PMSF 
20% glycerol 
1M KC1
Buffer A (pH 8,1)
20 mM Tris-acetate 
1 mM DTT (dithiothreitol) 
10 ug/ml PMSF 
20% v/v glycerol 
1% w/v Na-cholate
Buffer D (pH 8,1) 
20 mM Tris-acetate 
1 mM DTT 
10 ug/ml PMSF 
20% glycerol 
0.5% Na-cholate
0,1 M KC1 1 M KC1
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Buffer B (pH 8,1) Buffer E (pH 8,1)
20 mM Tris-acetate 20 mM Tris-acetate
1 mM DTT 1 mM DTT
10 ug/ml PMSF 10 ug/ml PMSF
20% glycerol 1% Na-cholate
1% Triton X-100 1,5M KC1
0,5M KC1
The pH of the buffer was adjusted to 8,1 with acetic 
acid before Na-cholate was added, since Na-cholate 
precipitates in the presence of acid.
Beef liver (1,5 kg) from a freshly slaughtered animal 
was cut into small pieces and immediately packed on 
ice. All subsequent procedures were carried out at 4 
degrees C. The pieces were washed in 1,15% cold KC1 
and then homogenized for five X 1 minute intervals 
with 4 volumes of buffer I in a Waring blender. 
Mitochondria were isolated by differential 
centrifugation (122) as outlined in Fig. 2. The 
mitochondria were washed twice in buffer I containing 
10 ug/ml PMSF (phenylmethylsulfonylfluoride) and 
sonicated for two X 30 second intervals with a 
sonicator at 60W (setting 18). The resulting 
suspension was centrifuged at 100,000 Xg for 90 min to 
separate the mitochondrial membrane fraction from the 
soluble matrix fraction. The mitochondrial membrane 
fraction thus obtained was then suspended at a
LIVER H O M O GEN ATE
CEN TR IFU G E 
800xg/20 minutes
SUPERNATANT P E LLE T
Resuspend in buffer
CEN TR IFU G E 
800xg/20 minutes
P ELLET 
nuclei 
cell debris
/---------
SUPERNATANTS
j C EN TR IFU G E 
1700x9/20 minutes
< 'I
SUPERN A TA N T P E LLE T
Crude mitochondria 
Resuspend in buffer 
Wash x3
W ASH ED M ITOCHONDRIA
FIG. 2: The differential centrifugation procedure to
obtain liver mitochondria
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concentration of + 40 mg/ml in buffer A. The mixture 
was stirred for 3 hours and then centrifuged at 
100,000 Xg for 90 min to separate the solubilized 
enzyme from the membrane fragments. To the 
solubilized enzyme fraction, saturated ammonium 
sulfate solution (pH 8,0) was added to constitute 35% 
saturation. The following equation was used to 
calculate the volume of saturated salt solution to be 
added:
x X 538,46, where x represents the volume 
1000
of enzyme suspension. The mixture was stirred for 15 
min and then centrifuged at 10,000 Xg for 10 min.
The pellet was discarded and the supernatant was 
further fractionated by the addition of saturated 
ammonium sulphate solution to yield a final 
concentration of 55% saturation. The following 
equation was used to calculate the volume of salt 
solution to be added. x X 444,44. The
1000
solution was stirred for 15 min and then centrifuged 
at 10,000 Xg for 10 min. The pellet was dissolved in
a minimal volume of buffer B (+ 50 ml). This enzyme 
solution was applied directly to a tandem set of 
columns composed of an initial Red Sepharose CL-6B 
(Pharmacia Fine Chemicals) column (1,5 x 20 cm) whose 
outlet was connected directly to a Blue Sepharose 
CL-6B (Pharmacia Fine Chemicals) column (2,5 x 30 
cm). The red column served as a "pre-column" to bind
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extraneous lipid material that contaminated the blue 
column when used alone. The red column matrix was 
discarded after six preparations. The flow rate 
during the application of sample was 20 ml/hr. The 
columns were first washed with 50 ml of buffer B, 
followed by 1 L of buffer C (flow rate 30 ml/min).
The red column was then disconnected and elution from 
the blue column was continued with 1,5 L of buffer D 
(30 ml/min) or until no protein could be detected at 
280 nm in the eluant. The enzyme was eluted from the 
column with 500 ml buffer E (20 ml/min). Fractions 
exhibiting ferrochelatase activity were combined (100 
to 300 ml) and dialyzed for 24 hours (two changes of 5 
L buffer), against 20 mM Tris-acetate buffer pH 8,1 
containing 1 mM DTT and 20% glycerol. The dialyzed 
fraction was divided into aliquots and stored at -20 
degrees C. To concentrate bovine ferrochelatase an 
aliquot (1 ml) was dialyzed for 24 hours against 2 L 
of 20 mM Tris-acetate buffer pH 8,1 and freeze dried.
2. Protein determination
Protein determinations on fractions that 
contained insolubilized membranes were done by the 
method of Lowry et al., (94).
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Reagents:
Solution A
2% Na2C03
0,05% sodium tartrate in 0,1M NaOH 
Solution B
This solution was prepared just prior to use by mixing
9 volumes of solution A with 1 volume 0,1% CuSO^ 51^0.
Folin Ciocalteu phenol reagent: (Merck) 1 ml Folin 
reagent was diluted with 2 ml H2 0 prior to use.
50 - 100 ul Protein sample was added to 5 ml solution 
B and allowed to stand at room temperature for 10 
min. Folin reagent (0,5 ml) was added and the sample 
mixed immediately. After 30 min the absorbance was 
read at 500 nm on a Pye Unicam PU 8800 ultraviolet 
spectrophotometer. Bovine serum albumin (bsa) 
standards were included in each assay. The protein 
concentration of each sample was calculated from a 
standard curve obtained by plotting ug bsa (10 - 500 
ug) against absorbance at 500 nm.
All other protein determinations were done with the 
Bio-Rad Protein Assay mixture (Bio-Rad Laboratories).
10 ml Of the Bio-Rad Assay mixture was diluted with 40
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ml of water. 5 ml Of this solution was added to 50 - 
100 ul protein sample, mixed and allowed to stand for 
5 min. Absorbance was read at 595 nm and compared to 
a standard curve of bsa (10 - 500 ug) measured against 
absorbance at 595 nm.
3. Ferrochelatase assay
Ferrochelatase activity can be measured directly by
three different methods: (1) Formation of haem as
determined by the pyridine haemochromogen assay
(123). This method gives the most reliable results
and greater sensitivity is obtained by using
mesoporphyrin IX instead of protoporphyrin IX as
substrate. The absorption peak of alkaline pyridine
mesohaemochromogen is different from that of
protohaemochromogen derived from pre-existing tissue
59 2 +haem (124). (2) Fe is used as substrate and
radioactive haem is determined after the reaction 
(125). This is a tedious and expensive method. (3) 
Measurement of porphyrin disappearance by a dual 
wavelength spectrophotometer. A disadvantage of this 
method is that porphyrin disappearance might not 
always be synchronous with haem formation. For 
instance, it has been reported that in pig liver 
mitochondria, the disappearance of mesoporphyrin 
apparently preceeded the formation of haem by as much 
as 30 min (125) .
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Ferrochelatase activity was measured by the pyridine 
haemochromogen method (123) as modified by H. Dailey, 
(128,84). The final reaction volume was 1 ml and 
consisted of 50 mM Tris acetate, pH 8,1; 5 mM DTT; 0,2 
mM ferrous ammonium citrate; 0,2% Triton X-100; 0,1 mM 
mesoporphyrin IX (Porphyrin Products, Logan, Utah) and 
the enzyme preparation. Mesoporphyrin IX was first 
dissolved in 0,1 M NH^ , adjusted to pH 8,1 with 
dilute HC1 and adjusted to the desired concentration 
with water.
The reaction was at 37 degrees C in the dark for 30
min and was terminated by addition of 0,5 ml 50 mM
iodo-acetamide. Then 360 ul of pyridine and 180 ul
of NaOH (1M) was added. The mixture was divided
equally between two cuvettes and 0,7 mg Na 2S 2 0  ^was
added to the one and 15 ul K.,Fe(CN) (3 mM) to thej 6
other. Care was taken that the N ^ S 20 4 was fresh and 
kept dessicated. Heat inactivated enzyme preparation 
was used as control. The difference spectrum of the 
reduced and oxidized pyridine haemochromogen was 
recorded with a Pye Unicam PU 8800 UV/Vis 
spectrophotometer and haem was calculated as follows:
3Haem (nmoles) = 10 .V.A E
A € mM
where V is the volume (ml) of alkaline pyridine 
solution and AE represents the difference in
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extintion between the maximum of the a band (547 nm 
for pyridine mesohaemochromogen) and the minimum 
occurring between the a and 3 bands (531 nm for
_ iemesohaemochromogen) . The value for AcmM for
pyridine mesohaemochromogen is obtained as follows:
547 ^.531tmM - mM = 21,7 (123). Ferrochelatase activity
is expressed as nmoles haem formed per min per mg 
protein.
4. Gel electrophoresis
Polyacrylamide cylindrical gel electrophoresis in the 
presence of 0,1% sodium dodecyl sulphate (SDS) was 
carried out in 10% gels according to the method of 
Laemmli (129). Polyacrylamide gel electrophoresis 
(PAGE) in the presence of SDS, separates polypeptide 
chains according to their molecular weights (130) .
The following stock solutions were prepared:
1. 1,875 M Tris HC1 pH 8,8
2. 0,625 M Tris HC1 pH 6,8
3. 20% SDS (w/v)
4. 30% acrylamide, 0,8% bis-acrylamide (w/v)
The following were mixed to prepare a 10% gel:
★ Extintion coefficient
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10 ml acrylamide stock solution 
6 ml 1,875 M Tris HC1 pH 8,8 
0,15 ml SDS stock solution 
3 ml ammonium persulfate solution (1,5% w/v)
1,5 ml N,N,N',N'-tetramethylenediamine (TEMED)
(0,5% v/v)
9,35 ml water
The mixture was degassed before addition of the 
crosslinking catalists ammonium persulfate and 
TEMED. The mixture was poured into glass tubes (12 x 
0,5 cm) of which the bottom end was sealed with 
parafilm. The gels were overlayered with 50 ul water 
to produce a flat top. Gels were allowed to 
polymerize at room temperature and left to stand for 2 
hours before use.
The following was mixed for the preparation of a 3% 
gel:
3 ml acrylamide stock solution 
6 ml 0,625 M Tris HC1 pH 6,8 
0,15 ml SDS stock solution
3 ml ammonium persulfate solution (1,5% w/v)
1,5 ml TEMED (0,5% v/v)
16,35 ml water
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After removal of the overlayered water from the 10% 
gel, 3% gel was poured onto the 10% gel and 
overlayered with water. The final ratio of 10% gel to 
3% gel was 3:1.
10 - 100 ug Of protein to be analyzed was incubated 
overnight at 37 degrees C, or boiled for 3 - 5  min in 
100 - 200 ul of the following solution:
10 ml 0,625 M Tris buffer pH 6,8 
10 ml SDS stock solution 
10 ml glycerol 
5 ml 2- mercaptoethanol 
0,001 g bromophenol blue 
65 ml water
Electrophoresis buffer was prepared as follows:
26,64 ml of 1,875 M Tris HC1 buffer, pH 8,8 
10 ml stock SDS solution 
28,827 g glycine
The volume was adjusted to two liters and the pH was 
adjusted to 8,3.
Electrophoresis buffer was poured into the cathode and 
anode tanks and 10 - 40 ug of solubilized protein was 
loaded onto each cylindrical gel by underlayering.
An electrophoresis system manufactured by Shandon
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Scientific Company Limited, London, England was used. 
Proteins were electrophoresed at room temperature 
towards the anode using a constant voltage of 50 volts 
across the 3% gel for 1 hour and 110 volts across the 
10% gel for 3 hours. The power supply was from 
Pharmacia Fine Chemicals, Uppsala, Sweden 
(electrophoresis constant power supply, ECPS 
2000/300).
After electrophoresis the gels were removed from the 
tubes and the position of the tracking dye marked with 
Indian ink. The gels were stained and proteins fixed 
overnight with 0,25% Coomassie brilliant blue R250, 
dissolved in methanol/acetic acid/water (30:7:63 by 
volume). Destaining was achieved by several changes 
of methanol/acetic acid/water (30:10:60 by volume).
5. Determination of molecular weight (131)
The molecular weight of ferrochelatase was determined 
by comparing its electrophoretic mobility using 
polyacrylamide gel electrophoresis in 10% gels in the 
presence of SDS, with those of protein standards of 
known molecular weights. SDS-PAGE of ferrochelatase 
and protein standards was carried out as described in 
section 4. The molecular weight standards were: 
albumin, ovalbumin, carbonic anhydrase and trypsin 
inhibitor. The migration distances of the standards 
and ferrochelatase were measured respectively on the
gels and the relative migration (Rf) values were 
calculated, where Rf is defined as:
Rf = distance protein has migrated from origin 
distance from origin to reference point
The position of the tracking dye (bromophenol blue) 
was used as the reference point. A calibration curve 
was constructed by plotting the Rf values of the 
standards against the logarithms of their 
corresponding molecular weights. The point on the 
calibration curve which corresponded to the Rf value 
of ferrochelatase was located, and the value on the 
logarithmic scale corresponding to this point was the 
estimated molecular weight of ferrochelatase.
6. Preparation of antibody to bovine ferrochelatase
Antibodies against ferrochelatase were raised as 
follows (132): 0,5 mg/ml purified bovine 
ferrochelatase was emulsified with an equal volume of 
complete Freunds adjuvant (Difco Lab, Detroit, U.S.A.) 
and injected subcutaneously into two New Zealand 
rabbits (2-4 kg). Three further injections of 0,2 mg 
antigen emulsified with incomplete Freunds adjuvant 
were given at monthly intervals. 5 ml Blood was then 
collected from the ear vein at two weekly intervals 
and allowed to clot overnight. It was centrifuged at 
400 Xg for 10 min and the serum was collected.
Antibody titer was determined with the enzyme linked 
immunosorbent assay (ELISA), using alkaline 
phosphatase labelled to goat antirabbit immunoglobulin 
G (Sigma St. Louis, U.S.A.) as conjugate (87). When 
the titre was satisfactory, 50 ml of blood was 
collected and the immunoglobulin G fraction was 
prepared.
7. Preparation of immunoglobulin G
The immunoglobulin fraction of ferrochelatase 
antiserum was prepared by the method of Harboe and 
Ingild, (133) , and modified as described by Anderson 
and Desnick, (49). Antibody was precipitated by the 
addition of 4 volumes saturated ammonium sulphate, pH
7,0,to 6 volumes of rabbit serum. After stirring for 
2 hours at 4 degrees C, the solution was centrifuged 
at 2,500 Xg for 20 min and washed twice with 1,5 M 
ammonium sulphate pH 7,0. Using this method, 
haemoglobin and albumin remain in the supernate and 
>90% of the IgG is recovered in the pellet (49). The 
pellet was resuspended in distilled water and 
extensively dialyzed against 5 mM potassium phosphate 
buffer, pH 7,4, containing 0,9% NaCl (5 changes of 
buffer in 5 days). The IgG fraction was divided into
1,5 ml aliquots and stored at -20 degrees C.
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8. Enzyme linked immunosorbent assay (ELISA) (134)
Because of the hydrophobic nature of ferrochelatase, 
it tends to form aggregates which makes it difficult 
to enter into gels under non-denaturing conditions or 
in the absence of detergents. Hence antibody detection 
by immunodiffusion or immunoelectrophoresis in agarose 
gels was unsuccessful. It was decided to use the 
enzyme-linked immunosorbent assay (ELISA) which is 
based on the same principles as a radioimmuno assay, 
except that an enzyme is used as a label for the 
antigen or antibodies instead of a radioisotope. The 
antigen (in this case ferrochelatase) is immobilized 
by passive absorption onto a solid phase (microtiter 
plate). Test rabbit sera are then incubated with the 
solid phase and antibody in the test sera becomes 
attached to the antigen on the solid phase. After 
washing to remove untreated serum components, a second 
antibody raised in goats against rabbit immunoglobulin 
G, linked to alkaline phosphatase is added and 
incubated. This will attach to rabbit immunoglobulin 
G already fixed to the antigen. Washing removes 
unreacted material and finally,substrate to alkaline 
phosphatase (para-nitrophenyl phosphate) is added 
which gives a stable yellow product. The substrate's 
colour change is a measure of the amount of conjugate 
fixed, and is proportional to the anti-ferrochelatase 
IgG level in the rabbit serum.
Methodology
0,25 ml Of ferrochelatase solution (10 ug/ml in 0,05 M 
NaHCO^ buffer pH 9,6), was added to some wells of a 
microtiter plate (Flow Laboratories, Irvine, Scotland) 
and left overnight at 4 degrees C. The plate was 
washed 3 times with phosphate buffered saline (pbs) 
containing 0,05% Tween 20 (M.A. Bioproducts, 
Walkersville, Maryland). Then 0,25 ml of 
ferrochelatase antiserum or IgG, diluted to desired 
concentrations with pbs containing 0,05% Tween 20 and 
0,5% bovine serum albumin (bsa), was added to the 
wells and incubated in a moist chamber at room 
temperature for 2 hours. Non-specific reaction of 
IgG against the antigen or surface of the microtiter 
plate was minimized by the inclusion of 0,05% Tween 20 
and 0,5% bovine serum albumin in the buffer (134,87). 
Antiserum and IgG of a non-immunized rabbit was used 
as negative controls. A well coated with 10 ug/ml bsa 
was used as blank against each well containing 
ferrochelatase. After washing 3 times with pbs 
containing 0,05% Tween 20; 0,25 ml of conjugate, 
diluted 1/1000 with pbs, 0,05% Tween 20, was added to 
each of the wells and incubated for 2 hours at room 
temperature.
The wells were washed again and 0,25 ml of substrate 
to alkaline phosphatase was added. The following 
reagents were mixed to prepare the substrate 
solution: 12 ml distilled water, 3 ml diethanolamine
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buffer (5 x concentrate, M.A. Bioproducts) and 10 ml 
of a para-nitrophenyl phosphate solution (M.A. 
Bioproducts). The para-nitrophenyl phosphate (40 
mg/vial) was dissolved in a solution of 2 ml 
diethanolamine buffer (5 x concentrate) and 8 ml E^ O. 
Optical density (0D 405 - 450 nm) of the reaction 
product was determined after 45 minutes on a Titertek 
Multiscan apparatus (Flow Laboratories).
RESULTS AND DISUSSION
A. Purification of bovine liver ferrochelatase
Table 1 summarizes the results of a typical 
purification of ferochelatase from 1 kg of bovine 
liver. The enzyme was purified 1006 fold with a 38% 
yield and appeared to be homogenous as displayed by a 
single band on a SDS-polyacrylamide gel (Fig.3).
These results were similar to those of Taketani S. and 
Tokunaga R., (120) who obtained a yield of 31% over a
434-fold purification of bovine ferrochelatase, 
whereas Dailey and Flemming (84) obtained a yield of 
49% and 2000 fold purification. Loss of purification
i.e. the appearance of a second band on SDS 
polyacrylamide gels after continued reuse of the blue 
column was also found (84). The use of a red 
Sepharose CL-6B column (which was omitted by Taketani 
and Tokunaga, (120) was found to extend the life of 
the blue column (84). The purified enzyme was stable
84
TABLE 1 PURIFICATION OF BOVINE
FERROCHELATASE
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FIG. 3: SDS-PAGE of bovine ferrochelatase. ' The
right lane contains 10 ug purified enzyme and
j
the left lane contains molecular weight 
markers. The arrows indicate the position
of the tracking dye (bromopnenol blue).
when stored at 4 degrees C in 20% glycerol, 1 mM DTT, 
10 ug/ml PMSF and 10 mM Tris acetate pH 8,1. There 
was a 10% loss of activity over one week in this 
buffer at 4 degrees C and a 50% loss after one month 
of storage at -20 degrees C. A considerable amount of 
enzyme was lost (+- 30%) during dialysis, possibly due 
to its non-specific absorption to the dialysis 
membrane.
The purified enzyme had a specific activity of 328 
nmol of mesohaem/mg prot/min, a value which is similar 
to that previously reported (120) . No mesohaem was 
formed nonenzymatically by heat treated enzyme 
preparation.The molecular weight of the enzyme as 
determined by SDS-polyacrylamide gel electrophoresis, 
appears to be approximately 44,000 (Fig. 4). This 
value is similar to the published molecular weight 
estimates of 40,000 (84) and 42,500 (120) found 
previously.
B. ELISA results
The isolation of homogenous bovine liver 
ferrochelatase permitted the preparation of an 
antibody specific to the enzyme. The best antibody 
titer was obtained after two months of the first 
injection of antigen. One rabbit showed a very low 
antibody response, therefore the serum of the other 
rabbit was used for antibody studies. Results using 
the ELISA technique were as follows:
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FIG. 4: Molecular weight determination of
ferrochelatase.
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Table 2: Effect of antigen concentration on antibody 
reaction expressed as OD values. Values are given as 
the mean of duplicate results. Serum dilutions of 
1/25 were used.
Ferroch. cone (ug/ml) Antiferroch. serum Control
serum
50 0,281 0,029
0 0,019 0,007
40 0,318 0,038
0 0,020 0,013
30 0,418 0,040
0 0,012 0,010
20 0,437 0,010
0 0,006 0,003
10 0,541 0,021
0 0,023 0,010
5 0,461 0,023
0 0,013 0,007
Conclusions:
A ferrochelatase concentration of 10 ug/ml gave the 
highest OD value. The corresponding blank values 
were low but scattered, while OD values of the 
non-immunized control rabbit serum were low and did 
not show any relation to antigen
concentration.
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TABLE 3: Effect of anti-serum dilution and IgG concentrations on antibody
reaction. The OD values given represent the means of duplicate 
results. A ferrochelatase concentration of 10 ug/ml was used 
throughout.
A.
Ferroche­
latase (ug/ml) 1
Antiserum dilution
_L _1 JL 1_ 1
Control
1
serum
1
dilution
1 1
100 50 25 10 5 100 50 25 10 5
10 0,350 0,450 0,541 0,511 0,423 0,019 0,029 0,038 0,040 0,071
0 0,004 0,012 0,023 0,007 0,012 0,007 0,005 0,013 0,008 0,029
Ferroche- Anti-ferrochelatase IgG (ug/ml) Control IgG (ug/ml)
latase (ug/ml) 37,5 75 125 250 37,5 75 125 250
10 0,355 0,465 0,567 0,528 0,011 • 0,022 0,029 0,049
0 0,003 0,007 0,010 0,006 0,007 0,010 0,003 0,006
Conclusions
An antiserum dilution of 1_ against 10 ug/ml of antigen gave
25
the highest OD value. The corresponding blank values were low, 
although scattered, while non-specific reaction of control serum 
increased as serum dilution decreased. An anti-ferrochelatase 
IgG concentration of 125 ug/ml against ug of antigen gave the 
highest OD value, the corresponding blanks were low, while non­
specific reaction of control IgG increased with increase in IgG
concentration. Although a serum dilution of 1_ reflects a low25
antibody titer, significant OD measurements could still be obtained
with a 1 .
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CHAPTER 4
PURIFICATION OF PROTOPORPHYRINOGEN OXIDASE
CHAPTER 4
Protoporphyrinogen oxidase (PPO) (EC 1.3.3.4)
The oxidation of protoporphyrinogen IX to 
protoporphyrin IX proceeds nonenzymatically under 
certain conditions. However evidence has accumulated 
that the reaction is enzyme dependent in all cells 
having aerobic metabolism (135-136). An enzyme that 
catalyses the oxidative removal of six hydrogens from 
protoporphyrinogen has been identified in yeast (135), 
E.coli (139,140), rat liver (86), human fibroblats, 
-erythrocytes,-leucocytes (70,71,72), beef liver (141) 
and barley mitochondria (136) . The enzyme responsbile 
for the oxidation of protoporphyrinogen was found to 
be anchored within the lipid bilayer of the inner 
mitochondrial membrane of rat liver mitochondria (142) 
with its catalytic site situated within the core of 
the inner membrane, being equally accessable to its 
substrate from both sides of the membrane. It has 
been shown that rat protoporphyrinogen oxidase is not 
translated on mitochondrial ribosomes, in contrast to 
that reported for yeast enzyme (143), but in the 
cytoplasma (144), inferring that the genes coding for 
rat and yeast enzyme have different locations.
PPO has been purified to 30 - 40% purity from rat 
liver (86) . It has been shown to be a monomer with 
molecular weight of 35,000, Km of 11 uM, pH optimum
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for the enzyme reaction at pH 8,7 and oxygen as the 
electron acceptor. The enzyme partially purified from 
yeast had a molecular weight of 180,000,Km of 4,8 uM 
and pH optimum of 7,45 (135). Partially purified 
human PPO had a pH optimum of 7,2, molecular weight of
32,000, Km of 0,16 uM for protoporphyrinogen IX and 
showed substrate inhibition by excess
protoporphyrinogen. The human enzyme was also able to 
catalyse mesoporphyrinogen IX to mesoporphyrin IX 
(145). Rat PPO does not catalyse the oxidation of 
coproporphyrinogen I, coproporphyrinogen III or 
uroporphyrinogen I.
Unsaturated fatty acids especially oleic acid 
stimulate partially purified barley PPO, suggesting 
that chromatographic treatment removes a lipid factor 
for which oleic acid could substitute (136). Since 
the enzymic conversion of protoporphyrinogen IX to 
protoporphyrin IX is not inhibited by cyanide, 2,4 
dinitrophenol or azide, disulfide bonds are not 
essential for activity (135). There is however, 
evidence that sulfhydryl groups might play a catalytic 
role in the enzymic reaction mechanism. The enzyme 
was protected against inhibition by
p-hydroxymercuribenzoate (a sulfhydryl blocking agent) 
in the presence of reduced glutathione (a sulfhydryl 
reducing agent) or protoporphyrinogen IX, but not by 
coproporphyrinogen III. This suggests that one or 
both of the vinyl side chains of protoporphyrinogen
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IX, may bind directly with the sulfhydryl groups of
the enzyme (135) . Sulfhydryl reducing agents such as
reduced glutathione, dithiothreitol and cysteine,
stimulate enzyme activity slightly at low
concentrations but inhibit enzyme activity at high
concentrations (86). PPO activity is also inhibited
in the presence of high salt concentrations, as well 
2 + 2 +as Cu and Co ions (135). Hemin (50 uM) inhibits 
yeast enzyme activity by 50% and inhibition is 
apparently non-competitive and irreversible (135). 
Human PPO is inhibited by metalloporphyrins such as 
Mn-,C0-,Cd-,Ni and Fe- protoporphyrin (haem) (145).
In E. coli, fumarate (139) and nitrate (146) serve as 
electron acceptors under anaerobic conditons, in 
contrast to mammalian PPO which is only active in the 
presence of molecular oxygen. Protoporphyrin 
formation in extracts of the obligate anaerobe 
Desulfovibrio gigas, was detected in the presence of 
several different electron acceptors under anaerobic 
conditions (147). The greatest PPO activity was 
observed with sulfite, NAD+, NADP+, FAD and FMN. When 
fumarate was used as an electron acceptor, rotenone 
inhibited the formation of protoporphyrin, suggesting 
that the flow of electrons from protoporphyrinogen to 
fumarate in D. gigas is flavoprotein mediated.
Visible spectral analysis of a PPO preparation from 
Yeast (135) revealed the presence of chromophoric 
cofactors, but the nature of the primary electron 
acceptor in eukaryotic systems has not previously been 
elucidated.
This chapter deals with the purification of bovine 
protoporphyrinogen oxidase to apparent homogeneity 
from bovine liver mitochondria by a method based on 
the purification of bovine ferrochelatase (84). An 
additional step, ion exchange chromatography using a 
Mono Q column on a fast protein liquid chromatography 
(FPLC)-system, gave a product with 68% yield and a 
870-fold purification. A yellow chromophore was 
associated with the enzyme at each stage of 
purification. Fluorescence and absorption 
characteristics of the chromophore indicated that it 
could be a flavin and more specifically, FAD (flavin 
adenine dinucleotide).
Riboflavin (vitamin B 2) consists of the sugar alcohol 
D-ribitol attached to 7,8-dimethyl isoalloxazine.
The vitamin occurs in nature almost exclusively as a 
constituent of the two flavin prosthetic groups, 
flavin mononucleotide (FMN) and FAD (Fig. 1). The 
flavins function as coenzymes because of their ability 
to undergo oxidation-reduction reactions. On 
reduction the yellow colour disappears since the 
reduced flavin is colourless, and on exposure to air, 
the yellow colour of the oxidized form appears. FAD 
was first demonstrated as a prosthetic group for 
D-amino acid oxidase (148). This enzyme belongs to a 
group of proteins termed flavoproteins, which catalyze 
oxidation-reduction reactions. FAD and FMN are 
firmly associated with these proteins throughout their
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Flavin mononucleotide (FMN) 
(Riboflavin monophosphate)
FIG. 1: Structure of FAD (148).
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purification. In fact, the flavin groups are usually 
only separated from the apo-enzyme by acid treatment 
or boiling (148). Many flavoproteins react directly 
with molecular oxygen to produce H 2 O . If the 
flavoprotein has a single flavin prosthetic group, the 
flavin moiety will be completely reduced by substrate 
and then reoxidized by C>2 .
SH2 + Enz - FAD _____  S + Enz - FADH2
Enz - FADH2 + 02_____  Enz - FAD + H2 02 (148)
Binding of a flavin to a protein often drastically 
changes its fluorescence and absorbance 
characteristics (152) and could also influence its 
reaction with molecular oxygen.
MATERIALS AND METHODS
1. Purification of protoporphyrinogen oxidase
All preparations were done at 0 - 4 degrees C. 
Purification of PPO was carried out based on the 
method of Dailey and Flemming, (84). The method was 
followed exactly as described in Chapter 3, section 
one, up to the 55% ammonium sulphate fractionation.
The 55% ammonium sulphate precipitate was dissolved in 
the following buffer to a concentration of
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approximately 2,5 mg/ml and dialysed overnight against 
the same buffer: 0,025 M Tris HC1 pH 8,7; 1 mM EDTA; 
0,1 mM dithiothreitol; 10% glycerol and 10 ug/ml PMSF 
(buffer A). Ten millilitres of the preparation was 
applied to a preparative Mono Q anion exchange column 
HR 10/10 (Pharmacia Biotechnology Uppsala, Sweden) 
connected to a Fast Liquid Chromatography (FPLC) 
apparatus supplied by Pharmacia Biotechnology 
Products. The following gradient was programmed into 
the FPLC apparatus:
Time (minutes) % Buffer B
0 - 40 10
40 - 60 10 -
60 - 70 100
70 - 80 10
Buffer B consisted of 0,5 M Tris HC1 pH 8,7; 1 mM 
EDTA; 0,1 mM dithiothreitol; 1% Na Cholate; 10% 
glycerol; 0,5 M NaCl and 10 ug/ml PMSF. The flow rate 
was 4 ml/min. The eluant was continuously monitored 
at 280 nm, while the 400 nm absorption and activity of 
the peaks were also determined. The fraction 
containing PPO activity eluted in the linear gradient 
between 10 - 50% B at approximately 35% B (Fig. 2).
To assess the purity of the active fraction prior to 
gel electrophoresis, an aliquot was dialysed overnight 
against 0,025 M Tris HC1 pH 7,5 and applied to a
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ProRPC HR 5/10 reverse phase column (Pharmacia 
Biotechnology) connected to a FPLC apparatus. It was 
eluted with a linear gradient of 50% acetonitrile, 
0,025 M Tris HC1 pH 7,5 buffer. The flow rate was 1 
ml/min.
2. Protein determinations
Protein determinations were done as described in 
Chapter 3, section 2 (Lowry and Biorad).
3. Protoporphyrinogen oxidase assay
PPO assays were done as described in Chapter 1, 
section 4, except that after one hour of incubation, 
100 ul of the reaction mixture was added to 2,9 ml of 
buffer (section 4.2) to determine fluorescence in a 3 
ml cuvette (pathlength 10 mm).
To test for the effects of various compounds on enzyme 
activity, the compounds were added to the reaction 
mixture 5 min. before the addition of substrate and 
enzyme activity was determined after one hour. Heat 
inactivated enzyme incubated with the same amount of 
compound served as control for each determination.
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4. Gel electrophoresis
SDS-polyacrylamide gel electrophoresis was done as 
described in Chapter 3, section 4.
5. Determination of molecular weight
5.1 Determination of molecular weight by 
SDS-gel-electrophoresis was done as described in 
Chapter 3, section 5. The molecular weight standards 
used were albumin, ovalbumin, trypsin inhibitor and
a -lactalbumin.
5.2 Molecular weight determination by gel filtration
The use of gel filtration chromatography for the 
determination of molecular weight and size of proteins 
is based on the ability of gel filtration media, such 
as Sephadex to separate molecules according to size. 
This determination is carried out by comparing an 
elution volume parameter (e.g. Kav) of the substance 
of interest, with the values obtained for several 
known calibration standards. A calibration curve is 
prepared by measuring the elution volumes of several 
substances, calculating their corresponding Kav values 
and plotting it versus the logarithm of their 
molecular weight. The molecular weight of the 
unknown substance can then be determined from the 
calibration curve, once its Kav value is calculated 
from its measured elution volume (149).
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A Sephadex G200 (Pharmacia Fine Chemicals) column (1,9 
cm x 25 cm) was packed and equilibrated (flow rate = 9 
ml/hour) with equal volumes of buffer A and B. The 
bed volume (Ve) was 74,6 ml. A solution of Blue 
Dextran 2000 (500 ul of a 1 mg/ml solution) was 
applied to the column to determine the void volume 
(Vo) and to check the column packing. Vo was 8,2 
ml. Molecular weight standards (5 mg/ml each) were 
dissolved together in 1 ml equilibration buffer and 
500 ul was applied to the column. The elution volume 
(Ve) in the same buffer of each of the standards was 
measured and the Kav was calculated:
Kav = Ve - V0 
Vt - V0
The molecular weight standards used were ribonuclease, 
chymotrypsin, ovalbumin and albumin. 500 ul Of PPO 
(0,2 mg/ml) in equilibration buffer was then applied 
to the column and the Ve determined. (The elution 
positions of the respective proteins were determined 
by monitoring the eluant at 280 nm)
6. Preparation of antibodies to protoporphyrinogen 
oxidase
Antibodies were raised against 90 - 95% pure PPO, the 
IgG fraction of the antiserum prepared and antibody 
titre determined as described in sections 6, 7 and 8 
of Chapter 3.
7. Affinity purification of anti-PPO IgG (150)
A homogenous preparation of PPO was covalently 
attached to CNBr-activated Sepharose 4B (Pharmacia 
Fine Chemicals). Proteins couple to CNBr-activated 
Sepharose-4B via their primary amino groups or similar 
nucleophylic groups (150). Anti-PPO IgG was then 
passed through the column, unbound material was washed 
away and the bound IgG was desorbed by a change in pH 
of the buffer.
A. Coupling of PPO
lg of freeze dried CNBr-activated Sepharose-4B was 
washed and reswollen on a scintered glass filter with 
1 mM HC1 (1 g gives 3,5 ml swollen gel). PPO was 
dissolved in NaHCO^ buffer (0,1M, pH 8,3) containing 
0,5M NaCl to a concentration of 1 mg/ml. The protein 
was mixed with the gel suspension and rotated 
end-over-end for two hours at room temperature. 
Residual active groups remaining on the gel after 
coupling were blocked with 0,2M glycine pH 8,0 (two 
hours at room temperature). To remove excess 
uncoupled ligand the gel was washed alternatively with 
high and low pH buffer solutions, four or five times 
(0,1M NaHCO^ buffer pH 8,3 and 0,1M Na-acetate buffer 
pH 4, both containing 0,5M NaCl). A column ( 1 x 5  
cm) was packed and equilibrated in 5mM potassium 
phosphate buffer pH 7,4, containing 0,9% NaCl.
B . Purification of IgG
3 ml Of concentrated anti-PPO IgG (1 mg/1 ml) in 5mM 
potassium phosphate buffer pH 7,4 was applied to the 
column and left for two hours at room temperature. 
Unbound material was washed away with the same buffer 
until no protein was detected in the eluant at 280 
nm. IgG bound to PPO was desorbed from the column 
with 0,2M glycine pH 2,7. The pH of the eluted IgG 
was immediately adjusted to pH 7,4 with 0,1M NaOH.
This procedure was repeated four or five times and the 
IgG was concentrated by freeze drying.
8. Studies on the chromophore
A. Determination of fluorescence spectra
A1. Fluorescence of the chromophore during the enzyme 
reaction.
The enzyme was concentrated by passing the dilute 
purified sample in buffer A through an analytical Mono 
Q anion exchange column and eluting it with a gradient 
of buffer B. Purified, concentrated PPO (0,1 mg/ml) 
was dialysed overnight against lOOmM Tris HC1 pH 
8,7. Protoporphyrinogen (5 uM) was incubated with 
three milliliters of PPO in the dark at 37 degrees C, 
EDTA, DTT, glutathion and Tween 20 were excluded in 
the reaction mixture. Protoporphyrin synthesis was
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measured against the inactivated enzyme as the control 
at different time intervals. Fluorescence excitation 
and emission spectra were also obtained from these 
aliquots and compared to that of FAD and FMN.
A2. Enzymatic digestion
The chromophore was released by trypsin digestion as 
previously described (151). The enzyme preparation 
was shielded from direct light during the treatment 
described below. Trypsin (0,07 mg) was added to 5 ml 
purified PPO (0,14 mg/ml) which had been dialyzed 
against 0,025M barbital sodium acetate buffer pH 8,0, 
freeze dried and reconstituted with the same buffer. 
After addition of a few drops of toluene, the mixture 
was placed in a thermostated waterbath at 45 degrees C 
for 4 hours, cooled and the pH adjusted to 4 with 
acetic acid. It was then heated to 80 degrees C for 
enzyme inactivation (5 min) and cooled to room 
temperature.
After oxygen was bubbled through the mixture for 30 
min the fluorescence excitation and emission spectra 
were determined on a Perkin Elmer 203 fluorescence 
spectrophotometer. These spectra were compared to
the fluorescence excitation and emission spectra of
- 7  .oxidized FAD (10 M) in 0,025M barbital sodium
acetate pH 4. Concentrated HC1 (50 ul) was then added 
to the oxidized digested preparation to hydrolyse the
105.
phosphate bonds of any FAD that might be present, 
which is then converted to FMN (151) . It was boiled 
for 15 minutes, cooled and the pH adjusted to 4 with 
5M sodium acetate solution. The fluorescence 
intensity at 520 nm (Aexc 465 nm) was measured and 
compared to that of the non-hydrolysed tryptic 
released chromophore.
A3. Acid hydrolysis
The chromophore was liberated from the enzyme by 
hydrolysing 0,14 mg of enzyme in 2 ml of 0,025M 
barbital sodium acetate pH 8,0 buffer, with 0,2 ml HC1 
(cone) for 45 min at 95 degrees C. It was cooled to 
room temperature, the pH adjusted to 4, treated with 
oxygen for 30 min, and the fluorescence determined.
All the fluorescence spectra were obtained at room 
temperature.
B. Purification of the chromophore and determination 
of absorption
The chromophore was released from the purified enzyme 
(0,5 mg/ml) with trypsin in 0,1M phosphate buffer pH
8,0. After it was treated with oxygen for 30 min,
200 ul of the preparation was applied to an analytical 
Mono Q anion exchange column HR 5/5 (Pharmacia) 
connected to a Pharmacia FPLC apparatus. The column
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was equilibrated with 0,1M phosphate buffer pH 8,0. 
Elution of the sample was isocratic at a flow rate of 
1 ml/min. (the bed volume of the column was 1 ml).
The eluant was monitored at 280 nm and absorption 
spectra were obtained of the peaks. The retention 
times of the peaks were compared to that of oxidized 
FAD and FMN (10 ug/ml) obtained from Sigma, St. Louis, 
U.S.A. Absorption spectra (at room temperature), of 
the peaks were compared to those of oxidized and 
reduced FAD and FMN, using a Pye Unicam PU 8800 UV/Vis 
spectrophotometer. Reduction was with lOug of solid 
KBH4 added to 1ml of the solution under anaerobic 
conditions.
RESULTS
A. Purification of PPO
The enzyme was purified to apparent homogeneity (Fig. 
3) from bovine liver mitochondria. It also eluted as 
a single peak off the reverse phase column at + 20% 
acetonitrile. The final yield was 68% with a 
870-fold purification (Table 1). PPO activity 
decreased by 50% after three months storage at -20 
degrees C, or after two weeks at 4 degrees C in buffer 
A. This loss in activity might be due to proteolytic 
activity, which also occurs in the case of purified 
ferrochelatase (117) even in the presence of PMSF.
When the enzyme was dialyzed to remove salt and
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FIG. 3: SDS polyacrylamide gel electrophoresis of
bovine protoporphyrinogen oxidase. The 
acrylamide concentration was 10%. The left 
lane contains 10 ug purified enzyme, the 
right lane contains molecular weight 
markers. The arrows indicate the position 
of the tracking dye.
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detergent, about 20% of enzyme was lost due to 
non-specific absorption to the dialysis membrane.
B. Molecular weight
The molecular weight as determined by SDS-gel 
electrophoresis was 33,500 as compared to the 
molecular weight standards (Fig. 4). The molecular 
weight as determined by gel filtration chromatography 
on a Sephadex G-200 column (25 x 1.9 cm) in the 
presence of equal volumes of buffer A and B was 33,250 
(Fig. 5). This was similar to the molecular weight for 
rat (86) and human (145) PPO.
C. Kinetic properties
The calculated Vmax of 1,6 ug of purified enzyme was 
9,6 nmol/hour. Corrections for non-enzymatic 
oxidation ranged from 10 - 30%. The Km for 
protoporphyrinogen IX at pH 8,7 was 16,6 uM as 
determined by the double reciprocal Lineweaver-Burk 
plot (Fig.6). The value is similar to values 
reported for partly purified PPO from rat liver and 
yeast mitochondria (86). Substrate inhibition 
occurred at substrate concentrations higher than 50 
uM. Substrate inhibition by protoporphyrin was also 
found in human protoporphyrinogen oxidase (145) .
D. Effects of various compounds on enzyme activity
1 1 0.
FIG. 4: Molecular weight determination of PPO by
SDS-PAGE using albumin, ovalbumin, trypsin 
inhibitor and a -lactalbumin as standards. 
The arrow indicates the position of PPO.
1 1 1.
FIG. 5: Molecular weight determination of PPO by gel
filtration chromatography. The standards 
used were ribonuclease A, chymotrypsin A, 
ovalbumin and albumin. The arrow indicates 
the elution position of PPO.
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Equimolar amounts of FAD or FMN did not significantly 
activate the enzyme. Activity was inhibited 37% by 
iodo-acetamide (lOmM). Inhibition by iodo-acetamide 
was also found previously (86) . Glutathione (5mM) 
inhibited the enzyme by 63%, which is similar to the 
55% inhibition found in rat PPO (86), whereas 7,5mM 
inhibited the enzyme completely. However,5mM 
glutathione does not inhibit PPO in human lymphocytes 
(72). As in the case of partly purified barley PPO 
(136), the isolated bovine enzyme was also markedly 
stimulated (by 66%) by oleic acid (1 mg/mg protein). 
It seems reasonable to postulate that the isolation 
procedures removed a lipid fraction normally 
associated with the membrane bound enzyme, and the 
oleic acid could substitute for this fraction.
E. ELISA results
When antibodies were raised against PPO, each of the 
two rabbits that were injected gave a good antibody 
titre after two months. However, when affinity 
purification of the respective IgG was attempted, only 
a small amount of purified PPO (20%) bound to 
CNBr-activated Sepharose 4B. This might have been 
due to PPO having a blocked amino-terminal end. In 
spite of this, enough PPO did bind to the gel to 
enable the purification of a sufficient amount of IgG.
1 1 4 .
The effect of antigen concentration on antibody 
reaction was similar to that outlined in Chapter 3, 
Table 2. A protoporphyrinogen oxidase concentration 
of 10 ug/ml gave the highest ELISA OD value, while a 
serum dilution of 1/200 gave OD values >0,400*
Table 2: Effect of IgG concentration on antibody 
reaction expressed as OD values. Values are expressed 
as the mean of duplicate results. A PPO concentration 
of 10 ug/ml was used.
PPO Anti-PPO IgG (ug/ml) Control IgG (ug/ml)
ug/ml 19 37,5 75 125 19 37,5 75 125
10 0,598 0,656 0,704 0,633 0,010 0,019 0,041 0,094
0 0,007 0,013 0,025 0,033 0,007 0,013 0,016 0,025
An IgG concentration of 75 ug/ml against 10 ug/ml of 
antigen gave the highest OD value. The corresponding 
blank values were low but increased with IgG 
concentration, while non-specific reaction of control 
serum also increased as IgG concentration increased.
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F. Characteristics of the chromophore
1. Fluorescence spectra of the bound and released 
chromophore
All active PPO fractions showed absorption in the 400 
- 500 nm region, indicating the’ presence of a 
chromophore. This chromophore was tightly bound to 
the enzyme since only prolonged extraction in hot 
mineral acids or proteolytic digestion could release 
it from the protein. Only then was it possible to 
oxidise the preparation with oxygen and to obtain 
fluorescence excitation and emission spectra which 
resembled those of oxidized flavins (151) (Fig. 7).
No fluorescence was detected of the bound chromophore, 
showing that the cofactor was in the reduced state. 
This could be explained by the presence of EDTA in the 
purification buffer, which upon illumination, causes 
specific reduction of flavins (151). EDTA was 
included throughout the isolation procedure (which was 
not shielded from direct light) to chelate trace 
amounts of Zn2 + which could form Zn^+ protoporphyrin 
with protoporphyrinogen (135).
2. Fluorescence of the chromophore during the 
enzyme reaction
No fluorescence was detected of the chromophore bound
FIG. 7: Fluorescence emission and excitation
spectra of trypsin treated PPO (0,14 mg/ml) 
in 0,025M barbital sodium acetate buffer 
pH4 at room temperature.
(____) Fluorescence excitation (X emiss 520)
and (--- ) fluorescence emission ( x  exc 465)
spectra of the preparation after treatment 
with oxygen. Excitation maxima (X emiss 
520) were 270,375 and 465 nm. At X exc 465 
fluorescence maximum was at 520 nm.
_7Oxidized FAD (10 M) showed the same 
fluorescence excitation and emission
spectra
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to the enzyme before or after treatment with oxygen. 
However, when the enzyme was incubated with low 
substrate concentrations in the absence of reducing 
agents or EDTA (section 8 A) a distinct fluorescence 
emission peak was noticed at 520 nm (3 arbitrary 
fluorescent units, where 1 0  units represent a full 
scale reading at 10,0 sensitivity setting). Excitation 
maxima were at 465 nm and 375 nm. These spectra were 
similar to that of oxidized flavoprotein (152) . 
Protoporphyrin synthesis under these conditions was 
approximately 10,0 nmoles/hour. Fluorescence at 520 (X 
exc 465 nm) was only noticed in the presence of low 
substrate concentrations, while the control showed no 
fluorescence at this wavelength. The flavin bound to 
the enzyme was possibly more accessable to oxygen in 
the presence of substrate and it was therefore more 
readily oxidized.
3. Absorption spectra
The absorption spectrum of intact PPO in buffer A was 
similar to that of a reduced flavoprotein (152) (Fig.
8 ). After extensive dialysis against 10 mM Tris HC1 
pH 8,7 to remove EDTA and DTT and saturation of the 
buffer with oxygen, an absorption spectrum was 
obtained which corresponded to that of a semi-oxidized 
flavoprotein with peaks appearing at 460 nm and 385 nm 
(Fig. 8 ).
1 1 8 .
FIG. 8 : Absorption spectra of PPO.
(____) Absorption spectrum of PPO in buffer
A.
(--- ) Absorption spectrum of PPO after
extensive dialysis against lOmM Tris HC1 pH 
8,7 and saturation of the buffer with
oxygen.
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Absorbance spectra which resembled those of fully 
oxidized flavins could only be obtained after the 
chromophore had been released from the protein, 
treated with oxygen and partially purified by FPLC on 
an anion exchange column (Fig. 9).
4. Identification and quantification of the flavin
Acid treatment of trypsin released chromophore changed 
its properties from those resembling FAD to those 
resembling FMN (e.g. 85% increase in fluorescence at 
520 (A exc 465 nm) (151) . It was therefore 
postulated that the chromophore bound to the intact 
enzyme could be FAD.
The amount of FAD present could be determined by 
comparing fluorescence at 520 nm (A exc 465 nm) of the 
oxidized trypsin treated preparation with that of a
—7 .known concentration of FAD: 10 ' M FAD gave a reading
of 9 fluorescence units; 0,7 mg enzyme (after tryptic 
digestion) gave, under similar conditions, a reading 
of 1,9 units. Ten arbitrary fluorescent units gave a 
full scale reading on the spectrofluorometer at 1 0 , 0  
sensitivity setting.
— 7The enzyme preparation contained: 1,9 X 10
9
= 2,11 x 10-8M FAD
A
B
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R
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FIG. 9: Absorption spectra of the partially purified
chromophore.
(____) Absorption spectrum of the tryptic
released chromophore after oxygen treatment 
and partial purification by FPLC in 0,1M 
phosphate buffer pH 8,0.
(--- ) Absorption spectrum of the same
preparation after treatment with KBH4 . 
Oxidized FAD (10 ug/ml) showed a similar 
spectrum as the oxidized chromophore and FAD 
reduced with KBH4 was similar to the 
chromophore reduced with KBH 4
121 .
At a molecular weight of 33 500 the 0,7 mg enzyme 
sample contained 2,08 x 10"% of enzyme. Therefore 
each enzyme molecule carries only one FAD molecule. 
This is not surprising since most FAD/FMN enzymes with 
more than one flavin per enzyme molecule have 
molecular weights >90 000.After partial purification 
of the oxygen treated chromophore by FPLC, the 
fraction which showed a typical oxidized flavin 
absorbance spectrum (Fig. 7), had the same retention 
time by the anion exchange column as a standard marker 
of oxidized FAD (3,77 minutes). Furthermore, marker 
FAD co-eluted with the oxidized cofactor in a single 
peak from the Mono Q column. Acid hydrolyzed 
cofactor (oxidized) showed the same retention time as 
oxidized FMN marker (2,40 minutes).
DISCUSSION
In this chapter the isolation to apparent 
electrophoretic homogeneity of the enzyme, 
protoporphyrinogen oxidase is reported. Whereas 
Poulson (8 6 ) obtained a specific activity of 0,5 
nmol/protoporphyrin /hr/ug protein for 30 - 40% pure 
PPO from rat liver, a specific activity of 6  
nmol/hr/ug protein was obtained for the bovine 
enzyme. The molecular weight of rat and bovine 
enzymes are similar. Recently the molecular weight of 
the human enzyme has also been determined at 32 000
(1 4 5) .
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A recent report (154) suggests that PPO is one of the 
lesser active enzymes in the haem biosynthetic pathway 
and on inhibition could lead to accumulation of 
protoporphyrinogen. Two factors, however, should be 
noted: As the enzyme is normally membrane bound it
has certain hydrophobic areas, but when in aqueous 
medium it is stripped from its normal lipid 
environment. It is confirmed that there is marked 
activation by oleic acid ( + 70%) . Furthermore it has 
been shown that 5mM glutathione (the conditions used 
in that report) inhibits the bovine, as well as rat 
PPO activity by + 50% (135). Taking these two factors 
into consideration, PPO activity on a units per gram 
of liver basis may be at least twice the published 
value, which could provide an even metabolic flux 
through the haem biosynthetic pathway.
It was noted at each stage of the purification 
procedure of PPO up to and including the final step 
that all active fractions showed absorption in the 400 
- 500 nm region. The absorption spectrum of the pure 
enzyme was similar to that of a reduced flavin and the 
extintion values at 360 nm and 450 nm shoulders were 
similar to a flavoprotein in the reduced state (152).
Although an absorption spectrum of the fully oxidized 
form could not be obtained, a spectrum similar to that 
of a semi-oxidized flavoprotein was obtained with 
peaks at 460 and 385 nm after removal of reducing
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agents in the buffer and treatment of the enzyme with 
oxygen. A fluorescence spectrum similar to that of an 
oxidized flavoprotein was noticed during the enzyme 
reaction in the absence of reducing agents and in the 
presence of low substrate concentrations.
We did not show any significant enhancement on 
activity on the addition of flavin, probably because 
of the tight binding of cofactor by the enzyme which 
was at all times fully saturated with coenzyme. On 
the other hand the report by Klemm and Barton (147) , 
that rotenone inhibits proto-porphyrin synthesis in an 
obligate anaerobe, suggesting that the reaction is 
flavoprotein mediated, supports the evidence reported 
here for FAD as the primary electron acceptor for 
protoporphyrinogen oxidase.
1 14 .
HYPOTHESIS
It has been postulated that ferrochelatase and 
protoporphyrinogen oxidase might form a stable complex 
in the inner mitochondrial membrane. The substrates 
for these enzymes are relatively large, highly 
reactive nonpolar compounds and the existence of such 
a complex would provide an efficient means of 
processing these compounds by allowing the product of 
one enzyme to immediately become the substrate for the 
next without ever having to leave the membrane 
environment (1 2 1 ) .
A model has been constructed which combines the 
evidence of FAD as coenzyme for PPO with the model put 
forward by Dailey (121) for the formation of haem by 
ferrochelatase as outlined in Chapter 3, Fig. 1.
This combined model is illustrated in Fig. 10. The 
formation of haem from protoporphyrinogen proceeds as 
follows (Fig. 10).
(a) PPO and ferochelatase (fc) exist as a complex in 
the inner mitochondrial membrane. FAD bound to PPO 
is in the reduced state
(FADH2 >- It has been shown in this chapter that the 
flavoprotein is in the reduced state during 
purification and that it is difficult to oxidize the 
enzyme by molecular oxygen in the absence of
substrate.
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FIG. 10: Formation of haem by protoporphyrinogen 
oxidase and ferrochelatase.
PPO = protoporphyrinogen oxidase 
Fc = ferrochelatase 
ppg = protoporphyrinogen 
pp = protoporphyrin
Reaction 1
For the formation of haem, iron binds to vicinyl 
sulfhydryl groups of ferrochelatase with the 
subsequent release of 2H+, prior to binding of 
protoporphyrin (PP) (121). It is suggested that the 
first reaction is binding of Fe2+ to Fc simultaneously 
or after binding of protoporphyrinogen (ppg) to PPO 
(b) .
Reaction 2:
FADH2 bound to PPO (b), is oxidized to FAD. This is 
based on the observation that a fluorescence spectrum 
similar to that of an oxidized flavoprotein was 
obtained during oxidation of ppg by PPO in the 
presence of low substrate concentrations, i.e. the 
flavin is more accessible to oxygen in the presence of 
substrate. (Illustration c shows the flavin bound to 
PPO in the oxidized form).
Reaction 3:
Oxidized FAD accepts 2H‘ from ppg and FADH is 
formed. FADH^ is reoxdized by 0^ with the formation 
of Ho0„. This cycle repeats itself three times in 
order to remove 6 H‘ from ppg for the formation of 
protoporphyrin (pp). When protoporphyrin (pp) is 
released from PPO or transferred to fc the flavin is
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again in the reduced form in the absence of substrate 
(d) .
Reaction 4:
The two hydrogen protons (2H+) of pp are exchanged for
. 2 +a molecule of ferrous iron (Fe ) and haem is 
released. The two released protons associate with 
the two cysteines of fc which had previously bound the 
iron (a), (Chapter 3, Fig.l).
CHAPTER 5
COMPARISON OP PROTOPORPHYRINOGEN
OXIDASE AND FERROCHELATASE
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CHAPTER 5
Comparison of protoporphyrinogen oxidase and 
ferrochelatase
In order to compare enzymes with complete accuracy, 
studies of the primary amino acid sequence has to be 
undertaken. However this involves a great degree of 
difficulty, especially in the case of a blocked amino 
terminus and utilizes large amounts of material. An 
alternative to this is sequencing of the protein at 
the DNA level. However this is an intricate and 
complex procedure and is currently beyond the range of 
techniques available to the author. Therefore it 
was necessary to employ indirect measurements to 
assess structural similarities.
This Chapter deals with (A) cross reaction 
immunological studies and (B) peptide mapping, to test 
the hypothesis that there are structural similarities 
between protoporphyrinogen oxidase (PPO) and 
ferrochelatase.
MATERIALS AND METHODS
A. Immunological studies
Antibodies were raised against homogenous 
ferrochelatase (Chapter 3,6) and the IgG fraction of
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the antiserum was prepared (Chapter 3,7). However, 
PPO was not always completely homogenous when injected 
into rabbits, therefore monospecific IgG was prepared 
by affinity chromatography (Chapter 4,7). Antibody 
titre was determined with the ELISA technique (Chapter 
4,8) and the IgG and antigen concentrations for 
optimum ELISA OD values were determined for each of 
the enzymes respectively (Chapter 3, table 2 and 3; 
chapter 4, table 2). Immunological cross reactivity 
was examined by incubating (a) 75 ug/ml of anti-PPO 
IgG against 10 ug/ml of ferrochelatase; (b) 125 ug/ml
of anti-ferrochelatase IgG against 10 ug/ml of PPO 
using the ELISA technique. Non-immunized rabbit sera 
and IgG were used as controls in all experiments and 
non-specific reaction was minimized by the inclusion 
of 0,5% bovine serum albumin in all IgG solutions.
B. Two dimensional peptide analyses
Two dimensional chymotryptic peptide analysis followed 
by autoradiography was done according to the method of 
Elder et al. (8 8 ).
Ferrochelatase and PPO bands,(stained with Coomassie 
Blue) were sliced from 10% SDS-polyacrylamide gels 
with a razor blade. Gel containing no protein was 
used as control. The slices were placed into 
siliconized tubes and washed extensively with 25% 
isopropylalcohol, then with 10% methanol to remove SDS
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and other contaminants. The slices were dessicated
under vacuum, overnight. The proteins were then 
• • • . 125radioiodmated with I (IMS-300, specific activity
about 557 mCi/ml; Amersham Ltd., Bucks, England) in 
the gel slice by a modification of the chloramine T 
method (155). The following components were added 
sequentially to the tubes containing the dried gel 
slices: 20 ul of sodium phosphate buffer (0,5 M, pH 
7,5),500 uCi 125j j_n ui, ancj 5 ui 0f chloramine T 
(1 mg/ml). The gels were allowed to absorb the liquid 
for 45 minutes, at which time 1 ml of sodium bisulfate 
(1 mg/ml) was added to stop the reaction. After 15 
minutes the bisulfite solution was removed and the gel 
slices were dialysed extensively against 1 0 % methanol 
in the cold. It was dialysed for 96 hours with 5 
changes of 2 L of 10% methanol. The gel slices were 
put in siliconized tubes and dessicated under vacuum, 
overnight. One ml of 50 ug/ml chymotrypsin 
(Worthington; 67 units/mg) in 0.05M NH^HCO^ buffer (pH 
8 ) was added to each tube. The samples were then 
incubated at 37 degrees C for 24 hours after which the 
supernatants were removed and lyophylized.
The samples were analyzed on cellulose-coated thin 
layer (TLC) plates without fluorescence indicator (20 
x 20 cm, Merck Darmstadt, Germany) (155) . The
samples were dissolved in 20 ul of Buffer I (acetic 
acid: formic acid: water, 15:5:80) . An aliquot of 1 
ul was counted on a gamma counter apparatus and 1 to 5
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ul (0,5 to lx 10 counts per minute) was spotted onto 
each plate. Electrophoresis was carried out at 10 
degrees C on a high voltage electrophoresis apparatus 
(Pharmacia Flat Bed Apparatus, FBE 3000) in Buffer I 
at lkV for about 1 hour. To ensure that the peptides 
of each sample migrated a constant distance, progress 
of electrophoresis was monitored by using 1 % fuchsin 
(w/v) solution in Buffer I. The dye was spotted at 
the opposite end from the sample and each plate was 
removed when the dye migrated 9,5 cm. The plates were 
dried and the peptides were chromatographed in a 
second dimension in Buffer II (butanol: pyridine: 
acetic acid: water; 32,5: 25: 5:20) containing 7%
2 ,5-diphenyloxazole (w/v).
The second dimensional separation was done by 
ascending chromatography (TLC) (8 8 ). The plates were 
run for approximately 4 hours in Buffer II before they 
were removed from the chromatography tanks and allowed 
to dry. The peptide patterns were visualized by 
autoradiography using Kodak ultrasensitive XAR-5 X-ray 
plates. Exposure times at -70 degrees C using image 
intensifying screens (Kodak, USA) ranged from 24 to 36
hours.
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RESULTS
A. ELISA results
When rabbit anti-bovine PPO IgG was tested against 
ferrochelatase and rabbit anti-bovine ferrochelatase 
IgG was tested against PPO, marked cross reactivity 
was found (Table 1). Anti-PPO IgG cross reacted 80% 
against ferrochelatase as compared to PPO, while 
anti-ferrochelatase IgG cross reacted 56% against PPO 
compared to ferrochelatase (Table 1). These results 
indicate that the two enzymes have common epitopes, or 
similar antigenic determinants. This can include, 
apart from similar steric tertiary protein domains, 
similar amino acid sequences.
TABLE 1
Antigen 
( 1 0  ug/ml)
IgG ELISA OD 
(405-450 nm)
PPO anti PPO IgG (75 ug/ml) 0,730+0,019
PPO control IgG (75 ug/ml) 0,007+0,001
Ferrochelatase anti PPO IgG (75 ug/ml) 0,576+0,015
Ferrochelatase control IgG (75 ug/ml) 0 ,0 1 0 +0 , 0 0 1
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TABLE 1
Antigen 
( 1 0  ug/ml)
IgG ELISA OD 
405-450 nm)
Ferrochelatase anti-ferrochelatase IgG 0,504+0,013
(150 ug/ml)
Ferrochelatase control IgG (150 ug/ml) 0,096+0,023
PPO anti-ferrochelatase IgG 0,309±0,013
(150 ug/ml)
PPO control IgG (150 ug/ml) 0,081+0,011
ELISA OD values are expressed as the standard error of 
the mean (SEM) of four measurements minus that of the 
blank (non-specific IgG reaction). Control values
were low and constant.
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B . Two dimensional peptide analysis
Comparison of the enzyme peptide maps showed marked 
similarity (Fig. 1); which indicate that PPO and 
ferrochelatase have peptides that are common to 
both. Similar results were obtained when the Elder 
peptide mapping procedure was repeated twice. The 
control showed no spots. The ferrochelatase 
autoradiograph revealed a greater number of peptide 
spots than that of PPO. Considering the homology that 
was indicated by immunological studies, this could 
have been expected, since the molecular weight of 
ferrochelatase is 42,000 against 33,500 for PPO.
However, other methods may produce different results,
since only approximately a third of the peptides
12 5generated by chymotrypsin are labelled by i. 
Radioactive iodine is mainly incorporated in the 
tryosine residues using the chloramine T procedure. 
Treatment with other proteolytic enzymes and or 
differing labelling procedures may produce maps . 
showing a greater degree of difference between the 
two enzymes (158) .
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DISCUSSION
These results indicate that ferrochelatase and PPO 
have epitopes and peptides common to both.
There may be several genetic explanations to account 
for these similarities. It is suggested that the 
most plausible explanation for the high degree of 
homology between them is that the genes coding for 
them share a common ancestry. Gene duplication and 
subsequent divergence due to mutation would have led 
to the differences which now exist between them (157). 
In a recent publication (163) , considerable amino acid 
sequence homology was found between two enzymes 
catalyzing consecutive steps in the methionine pathway 
in Escherichia coli. The authors suggested that these 
two enzymes might have evolved from a common ancestral 
gene. The original gene may have been duplicated with 
the copies ultimately residing at different sites on 
the E.coli chromosome. Subsequently mutations have 
occurred in the ancestral enzyme genes leading to 
specialization of the encoded proteins. According to 
a proposal put forward 40 years ago (164) the 
biosynthetic pathways as we know them today have been 
progressively built backwards from the final 
metabolite of the pathway. This theory was 
rejuvenated based on gene duplication followed by 
mutation (165) mainly taking into account the 
hypothesis of gene duplication as an important factor 
of evolution (166).
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CONCLUSION
This thesis was undertaken to determine if there was 
any interrelationship between protoporphyrinogen 
oxidase and ferrochelatase, with particular reference 
to PV and EPP. The background to porphyria and in 
particular PV and EPP and the evidence to date whether 
the two diseases may be interrelated, ate outlined in 
the introduction. In chapter 1, PPO was measured in 
both EPP and PV patients and in the offspring of PV 
patients. In the same subjects, protoporphyrin 
formation by mitogen stimulated lymphocytes with ALA 
as substrate and in the presence of an iron chelator 
or iron, provided an indirect measurement for 
ferrochelatase. The results provided strong evidence 
that PPO and ferrochelatase were both defective in 
both diseases. Furthermore, the studies in the 
offspring of PV subjects showed normal ferrochelatase 
activity even in those with reduced PPO activity, 
which would suggest that ferrochelatase deficiency is 
only manifested after puberty. In chapter 2, detailed 
studies in PV families suggested that reduced PPO 
activity may be a marker for carriers who evolve into 
PV patients in adulthood. The data support the basic 
genetic concept for this disease that it is autosomal 
dominantly inherited.
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Chapters 3 and 4 are concerned with the purification 
of ferrochelatase and PPO and the production of 
antibodies. The purification of ferrochelatase was 
based on a method previously described by Dailey 
(84) . To date PPO had not been purified. This was 
achieved by anion exchange chromatography using a 
Pharmacia FPLC apparatus. Throughout the purification 
procedure all active fractions showed absorbance in 
the 400-500 nm region and the chromophore was 
suspected to be a flavin. Preliminary studies 
suggested that this was FAD.
The precise biochemical basis for the deficiency of 
the two enzymes in PV and EPP has to await the 
purification and characterization of the enzymes from 
diseased subjects. Purification and characterization 
of the normal enzymes is a necessary and important 
step in that direction. Comparison of the two enzymes 
on some biochemical aspects shows some interesting 
points:
(a) Location
Protohaem is formed in the mitochondrial matrix (159), 
therefore the particular submitochondrial location of 
the final enzymes of the haem pathway may be important 
for the transport of substrates from the cytoplasm to 
the mitochondrial matrix. It has been established 
that coproporphyrinogen oxidase is associated with the
cytoplasmic side of the inner mitochondrial membrane 
(160), whilst protoporphyrinogen oxidase was found 
within the lipid bilayer with its catalytic site 
situated within the core of the inner membrane. The 
active site for ferrochelatase was found to be 
associated with the matrix side of the inner 
mitochondrial membrane, with the enzyme physically 
spanning the membrane. The location of these three 
enzymes in close vicinity to each other, provides an 
efficient means of transporting porphyrin substrate 
from the cytoplasm across the inner mitochondrial 
membrane to the active site of ferrochelatase.
It has been postulated that these three enzymes form a 
stable complex in the membrane, because the existence 
of such a complex would provide an efficient means for 
processing their nonpolar substrates, allowing the 
product of the one enzyme to immediately become the 
substrate for the next. A model was presented in 
chapter 4 based on this postulation together with the 
evidence for FAD as coenzyme for PPO, whereby a 
complex of ferrochelatase and PPO combines with the 
substrates protoporphyrinogen and iron to form haem.
(b) Activity
Both enzymes have sulfhydryl groups present in the 
active site, however evidence is that iron binds to 
sulfhydryl groups in ferrochelatase, whereas
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protoporphyrinogen binds to the sulfhydryl groups in 
PPO. However, the possibility that protoporphyrin 
might bind to sulfhydryl groups in ferrochelatase is 
not excluded (121). Furthermore, both enzymes are 
activated by lipids, probably due to their lipid 
environment in vivo. There are also distinct 
differences between the enzymes. For instance PPO is 
inhibited by high salt concentrations but not 
ferrochelatase; and metals play a much greater role in 
ferrochelatase activity. PPO needs a primary electron 
acceptor to remove six electrons and six protons (H+) 
from protoporphyrinogen. The primary 
electron-acceptor is not likely to be molecular 
oxygen. This statement is based on the finding that 
spectral analyses of PPO reaction mixtures indicated 
that semi-reduced forms of protoporphyrinogen IX 
accumulate only in the non-enzymic reaction mixture 
(161) . This suggest that during auto-oxidation 
semi-reduced porphyrins are formed due to the 
preferential loss of hydrogens from one side of the 
protoporphyrinogen nucleus (162) , whereas in the 
presence of PPO all six hydrogen atoms are apparently 
removed very rapidly from the protoporphyrinogen ring 
by the enzyme. These findings suggest that the enzyme 
uses a coenzyme that is able to undergo 
oxidation-reduction reactions, i.e. a flavin. 
Ferrochelatase in contrast removes only two protons 
(2H+) from protoporphyrin when iron is inserted, for 
which an electron acceptor is not needed.
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In the final chapter, antibodies raised against 
ferrochelatase and PPO showed marked cross reactivity 
against the other enzyme and peptide maps for each 
enzyme showed marked structural similarities between 
them. In addition to clinical and biochemical 
evidence interrelating PPO and ferrochelatase, these 
last two experiments provided immunological and 
structural evidence for homology between them. The 
conclusion that one can arrive at from all these 
studies is that there is strong evidence that these 
two enzymes are indeed interrelated, which could be 
clinically expressed in EPP and PV.
Production of homogenous enzyme and antibodies 
provides a good base for extending studies on EPP and 
PV to the DNA level. Obtaining the primary amino acid 
sequence for the enzymes would allow for construction 
of oligonucleotide probes which could be used to 
screen a human genomic library to locate the genes for 
these enzymes. An alternative method for locating the 
genes would be the construction of an expression 
vector library, which could be screened using the 
monospecific antibodies. Extending this study to the 
specific genes implicated in the porphyria disorders 
would lead to a greater understanding of the molecular 
pathology of these hereditary dysfunctions.
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